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ABSTRACT 
Most solid tumours rely on glycolysis for energy production, even in conditions of high 
oxygen tension (‘‘aerobic glycolysis’’, also known as the Warburg effect), giving rise to enhanced 
lactate production. This lactate production is responsible for extracellular acidification, which, 
conditioning the tumour environment, favours tumour invasion and suppresses anticancer immune 
response. Transport of lactate across the plasma membrane is mediated by a family of proton-
coupled monocarboxylate transporters (MCTs), which comprises 14 members. The isoforms 
MCT1-MCT4 are proton symporters that exhibit different affinities for lactate, leading to different 
levels of tissue expression. Since some MCT isoforms (especially MCT1 and MCT4) play a role 
in the intracellular pH homeostasis, by exporting the accumulating lactic acid, they are up-
regulated in glycolytic tumours, where high levels of lactate are produced, such as high grade 
gliomas, colorectal carcinomas and lung cancer. However, the role of MCTs in tumours is far from 
being well understood and their potential as therapeutic targets is poorly explored, being the main 
aim of this work to further elucidate the significance of MCT expression in solid tumours. 
Thus, MCTs expression and their clinic-pathological value were evaluated in human series 
of colorectal, cervical, gastric and breast carcinomas. Also, MCT regulation by chaperones was 
further investigated by analysing CD147 in cervical, gastric and breast carcinomas series, as well 
as performing a screening in colorectal, breast, lung and ovary tumour samples, where CD44 
expression was evaluated, as a putative MCT chaperone, in addition to CD147. Finally, some in 
vitro studies were performed, to determine the contribution of MCTs to cancer cell metabolic 
profile and viability. 
Importantly, up-regulation of MCTs, in particular MCT1, was found in colorectal, cervical 
and breast carcinomas, but not in gastric carcinomas, which, in fact, showed a decrease of MCT4 
along towards malignancy. Also, MCT1 was associated with poor prognosis, especially in breast 
carcinomas, as well as in gastric carcinoma where MCT1/CD147 co-expression was associated 
with poorer patient prognostic. Also, as anticipated, CD147 was found to be co-expressed with 
both MCT1 and MCT4 in the large series studied (cervical, gastric and breast carcinomas). In the 
tumour screening, CD44 was only associated with MCT1 in lung cancer, however, series were 
very small and some results warrant further attention. Finally, the in vitro studies showed a CHC-
induced inhibition of cell proliferation in human breast cancer cell lines that was, in some cases, 
accompanied by metabolic alterations. 
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In conclusion, the results presented in this thesis have an important impact on the 
comprehension of MCT contribution to malignant phenotype and pave the way for further studies 
aiming to the development of cancer therapies directed to MCTs. 
 
  xi
 
RESUMO  
A maioria dos tumores sólidos depende da glicólise para produção de energia, mesmo em 
condições de alta pressão parcial de oxigénio (“glicólise aeróbia”, também conhecida como o 
efeito de Warburg), dando origem a uma maior produção de lactato. Esta produção de lactato é 
responsável pela acidificação extracelular, o que condiciona o ambiente do tumor, favorecendo a 
invasão tumoral e a supressão da resposta imune contra o tumor. O transporte de lactato através da 
membrana plasmática é mediado pelos transportadores de monocarboxilatos (MCTs), que 
pertencem a uma família composta actualmente por 14 membros. O transporte mediado pelas 
isoformas MCT1-MCT4 é um simporte com protões e cada isoforma possui afinidade distinta para 
o lactato, apresentando uma distribuição diferente nos vários tecidos. Uma vez que algumas 
isoformas (especialmente o MCT1 e o MCT4) desempenham um papel na homeostasia 
intracelular, ao exportar o ácido láctico acumulado, está descrito um aumento destas isoformas em 
alguns tumores glicolíticos, onde são produzidos níveis elevados de lactato, como seja em gliomas 
de alto grau, carcinomas colorectais e cancro do pulmão. No entanto, o papel dos MCTs em 
tumores está longe de ser completamento elucidado e o seu potencial como alvo terapêutico ainda 
se encontra pouco explorado, sendo o objectivo principal deste trabalho caracterizar o papel dos 
MCTs em tumores sólidos. 
Assim, a expressão e valor clínico-patológico dos MCTs foram avaliados em séries humanas 
de carcinoma colorectal, do colo do útero, do estômago e da mama. Para além disso, a regulação 
dos MCTs por proteínas chaperonas foi investigada, analisando a expressão da CD147 nas séries 
de carcinoma do colo do útero, do estômago e da mama, assim como a realização de um estudo-
piloto onde a expressão da CD44, outra possível chaperone dos MCTs, foi avaliada em tumores 
colorectais, da mama, do pulmão e do ovário, para além da CD147. Finalmente, alguns estudos in 
vitro foram realizados de modo a elucidar a contribuição dos MCTs para o perfil metabólico e 
viabilidade das células tumorais. 
De notar que um aumento na expressão dos MCTs, em particular do MCT1, foi encontrado 
nos carcinomas colorectal, do colo do útero e de mama, mas não nos carcinomas gástricos, que, na 
realidade, mostraram uma diminuição do MCT4 com o aumento da malignidade. Além disso, a 
expressão do MCT1 foi associada a um pior prognóstico, em especial nos carcinomas da mama, 
assim como no carcinoma gástrico, onde a co-expressão do MCT1 com a CD147 foi associada a 
um pior prognóstico do paciente. Como antecipado, a CD147 estava co-expressa quer com o 
MCT1 quer com o MCT4, quando avaliado nas séries de maior dimensão (carcinomas do colo 
uterino, gástrico e da mama). No estudo-piloto, a CD44 estava associada apenas com o MCT1 no 
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cancro do pulmão, no entanto, o tamanho das séries era muito reduzido e alguns dos resultados 
obtidos merecem ser explorados no futuro. Finalmente, os estudos in vitro mostraram que o 
tratamento com CHC induz uma inibição da proliferação celular em linhas celulares de tumor da 
mama, a qual foi, em alguns casos, acompanhada por alterações metabólicas. 
Em conclusão, os resultados apresentados nesta tese têm um grande impacto na 
compreensão da contribuição dos MCTs para o fenótipo maligno e abrem caminho para estudos 
posteriores que visem ao desenvolvimento de terapias anti-tumorais direccionadas aos MCTs. 
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AIMS AND THESIS LAYOUT 
Accumulation of lactate in the tumour microenvironment is a widely described event and 
this lactate has been associated with poor prognosis in cancer patients. Also, lactate has been 
recently described as the key metabolic intermediate in the metabolic symbiosis between 
glycolytic cancer cells and oxidative cancer cells. Monocarboxylate transporters (MCTs), as 
facilitators of lactate efflux from cells, mainly the isoforms 1 and 4, are key proteins in cancer cell 
metabolism and survival. Actually, these membrane proteins have been pointed out several times 
as promising cancer therapeutic targets. However, studies on MCT contribution to the malignant 
phenotype are still scarce and more basic scientific efforts on this matter are needed, which will 
probably result in important findings, with clinical implications. 
Therefore, the main aim of this thesis was to further characterise MCT expression in 
different human solid tumours, as well as to give a contribution to understand the role of MCT in 
cancer cell hyper-glycolytic phenotype, providing evidence for the exploitation of MCTs as 
potential targets for cancer therapy. 
 
In Chapter 1, a general introduction to the thesis subject is provided, with special emphasis 
on MCT family members, their role in homeostasis and disease, as well as their regulation and 
inhibition. The current knowledge on MCT contribution to tumour microenvironment, lactate 
production and its contribution to the malignant phenotype and the potential of MCTs as targets in 
cancer therapy are also reviewed. 
 
In Chapters 2-5, MCT characterisation in human solid tumours, including results already 
published, is presented, giving a contribution to the knowledge on MCT behaviour in cancer 
metabolic adaptations. Characterisation of MCT expression in colorectal carcinoma is presented in 
Chapter 2. In Chapter 3, MCT expression, as well as expression of MCT1 and 4 chaperone, 
CD147, in cervical carcinoma are shown. Characterisation of MCT and CD147 expression in 
gastric carcinomas is included in Chapter 4. Finally, Chapter 5 provides the results obtained in 
breast cancer, both in human samples and in in vitro models. Besides the published results on 
MCT and CD147 characterisation in breast carcinoma, Chapter 5 also includes results, already 
submitted for publication, where the expression of MCTs was associated with proteins implicated 
in the metabolic adaptation to hypoxia, i.e. CAIX and GLUT1. Also, unpublished results of in 
vitro MCT inhibition in human breast cancer cell lines, to evaluate the contribution of MCTs for 
cancer cell metabolic profile and survival, are presented in Chapter 5. 
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Moreover, as MCT regulatory mechanisms are still poorly elucidated, Chapter 6 presents 
the published results of a screening study (in a commercial tissue microarray containing breast 
carcinomas, colon adenocarcinomas, non-small cell lung cancer and ovarian adenocarcinomas), 
where the recently described MCT regulation by CD44 is explored, in addition to CD147. 
 
Finally, in Chapter 7, the main conclusions of Chapters 2-6 are summarised and further 
discussed, and some important future directions are suggested. 
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1.1. MONOCARBOXYLATE TRANSPORTERS 
Monocarboxylic acids play a major role in cellular metabolism, with lactate, the end product 
of glycolysis, being especially important. For some highly glycolytic tissues such as red blood 
cells, white muscle and tumour cells, which rely on glycolysis for energy supply, lactate is 
produced in high rates and so must be rapidly expelled out of the cell, to maintain high rates of 
glycolysis. On the other hand, in brain or cardiac and red muscles, where lactate is oxidised as a 
respiratory fuel, or kidney and liver were lactate is the major gluconeogenic substrate, lactate must 
be rapidly transported into the cell [1]. Transportation of monocarboxylates through the plasma 
membrane was originally thought to be via non-ionic diffusion of the free acid, however, 
following demonstration that lactate and pyruvate transport into human erythrocytes could be 
strongly inhibited after treatment with chemicals [2], a specific monocarboxylate transport 
mechanism was recognised. After extensive characterisation of monocarboxylate transport in 
different cell types like erythrocytes, cardiac myocytes and hepatocytes, among others, the 
different characteristic observed led to the hypothesis of the existence of a family of 
monocarboxylate transporters (for review see [3]). 
 
 
1.1.1. THE MCT FAMILY  
The monocarboxylate transporter (MCT) family is presently composed by 14 members 
(Table 1), and belongs to the major facilitator superfamily [4]. MCTs are encoded by the SLC16 
gene family [5], which is conserved among species, including rat, mouse, chicken and others. 
Hydropathy plots predict 10-12 α-helical transmembrane domains (TMD) for MCT members, with 
both N- and C-termini located within the cytoplasm [5], as illustrated in Figure 1 for MCT1. Like 
members of other families, MCTs exhibit the highest sequence conservation in TMDs and in the 
shorter loops between TMDs. In contrast, the hydrophilic regions (N- and C-termini as well as the 
loop between TMDs 6 and 7) show little conservation, indicating that these regions are unlikely to 
be directly involved in transport, being probably critical in other functional aspects such as 
substrate specificity or regulation of activity [6]. Theoretical predictions [6] and experimental 
evidence [7,8] indicate that none of the MCT family members is glycosylated. To function, an 
MCT translocates a proton and a monocarboxylate through the plasma membrane by an ordered 
mechanism in which H+ binding is followed by monocarboxylate binding to the protonated 
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transporter [9]. Therefore, MCT activity is dependent on both substrate concentration and proton 
gradient. 
 
Table 1. The human SLC16 family of transporters (from [10]). 
 
 
Although lactate is the monocarboxylate whose transport across the plasma membrane is 
quantitatively more important, MCTs are also important for the transport of many other 
metabolically important monocarboxylates such as pyruvate, the branched-chain oxoacids derived 
from leucine, valine and isoleucine, and the ketone bodies acetoacetate, β-hydroxybutyrate and 
acetate [1]. Consequently, MCTs have a central role in mammalian cell metabolism and are 
critical for the communication between cells [3], as illustrated in Figure 2. 
Besides being a family of 14 members, only the first four (MCT1-MCT4) have been 
demonstrated experimentally to facilitate the proton-linked transport of metabolically important 
monocarboxylates [8,11-13]. MCT3, formerly known as REMP (from retinal epithelial membrane 
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protein), was firstly described the chicken retinal pigment epithelium [14] and then functionally 
characterised and renamed MCT3 [8]. Subsequent studies showed the very particular distribution 
of MCT3, limited to the retinal pigment and choroid plexus epithelia [15-18], indicating that these 
isoform seems to be a very specialised MCT. Therefore, this introduction will only focus on 
MCT1, MCT2 and MCT4 isoforms, whose function is responsible for the name of the family of 
transporters. 
 
Figure 1. MCT1 protein diagram (from [19], see Appendix I). 
 
 
1.1.1.1. MCT1 
Most of the early functional studies on plasma membrane lactate transport were performed 
using red blood cells, since a homogeneous population of these cells could be readily obtained. 
However, MCTs were biochemically studied for many years before their molecular 
characterisation was performed [2,20-23]. The discovery and cloning of a mutant allele encoding a 
protein with preferential transport of the cholesterol precursor mevalonate (Mev) in Chinese 
hamster ovary cells resulted in new information about the molecular features of MCTs. When 
characterising the Mev mutation [24], it was found that the wild-type protein preferentially 
transported pyruvate [25]. This novel protein was designated monocarboxylate transporter 1 
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(MCT1) and kinetically resembles the biochemically characterised erythrocyte MCT. 
Human MCT1 gene, SLC16A1 (for review see [19], Appendix I), firstly cloned in 1994, by 
Garcia and colleagues [26], is located chromosome 1 (1p13.2-p12). Structural gene organisation as 
well as isolation and characterisation of SLC16A1 promoter was achieved in 2002, by Cuff and 
Shirazi-Beechey [27]. SLC16A1 comprises 5 coding exons [27] and, although there are no 
evidences for alternative splicing in the 5’ and 3’ untranslated regions (UTR) [1], 6 transcripts 
have been identified, 4 resulting in proteins of different sizes and 2 with no translation product 
(ENSG00000155380 [28]). MCT1 functional protein is composed by 500 amino acids and has a 
molecular weight of 53,958 Daltons (P53985, [29]). 
 
 
Figure 2. Metabolic pathways involving monocarboxylate transport across the mitochondrial and plasma 
membranes (adapted from [1]). Abbreviations: Ac, acetoacetate; βHB, β-hydroxybutyrate; Glc-1-P, glucose 1-
phosphate; Glc-6-P, glucose 6-phosphate. 
 
MCT1 has an ubiquous distribution in human tissues, with higher expressions in heart and 
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muscle [6,12,30]. Although conserved among species, MCT1 expression levels in tissues is 
species-specific [31]. The wide pattern of expression observed for MCT1 may be explained by its 
substrate affinities that indicate that MCT1, with intermediate substrate affinities, may be involved 
in both uptake and efflux of monocarboxylates from cells (Table 2). MCT1 transports a variety of 
substrates including short chain (C2-C5) unbranched aliphatic monocarboxylates such as acetate 
and propionate. Monocarboxylates with C2 or C3 substitutions (excluding amino- and amido-
substitutions) are also transported or even preferred (e.g. pyruvate, L-lactate, acetoacetate and β-
hydroxybutyrate) [32-34]. The simplest monocarboxylate, formate, is a poor substrate (Km>100 
mM) whereas bicarbonate, dicarboxylates, tricarboxylates and sulphonates are not transported [5]. 
Also, as can be seen in Table 2, MCT1 is stereoselective for lactate but not for β-hydroxybutyrate. 
Although plasma membrane expression is required to the export or uptake of 
monocarboxylates, MCT1 has also been described to be expressed in mitochondria [35-41] and 
peroxisome [42]. In these organelles, MCT1 is believed to participate in a lactate oxidation 
complex to maintain organelle redox and proper functioning. 
 
Table 2. Km values (mM) of different mammalian MCT isoforms for a range of monocarboxylates. 
 MCT1[33,34,43] MCT2[44] MCT4[13,45] 
L-Lactate 2.2-4.5 0.7 28.0-34.0 
D-Lactate 51.0  519.0 
Pyruvate 0.6-1.0 0.08 153.0 
L-β-hydroxybutyrate 8.1-11.4  824.0 
D-β-hydroxybutyrate 8.1-10.1 1.2 130.0 
Acetoacetate 5.5 0.8  
Propionate 1.5   
Acetate 3.5   
 
 
1.1.1.2. MCT2 
In 1995, the second MCT isoform was cloned and sequenced from a hamster liver cDNA 
library [46]. The SLC16A7 gene, which encodes for MCT2, is located in chromosome 12 (12q13) 
[12], comprises 5 coding exons and, although only one transcript is identified in a public database 
for human SLC16A7 (ENSG00000118596, [28]), there is evidence for alternatively spliced mRNA 
species in human and rat [12,31], but no evidence of splice variants of the protein. This isoform 
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shares approximately 50% sequence identity with MCT1, contains 478 amino acids and has a 
molecular weight of 52,186 Da (O60669, [29]). 
Northern blot analysis of human tissues showed a much more restricted tissue distribution of 
MCT2, as compared to MCT1, with MCT2 mRNA found in spleen, heart, kidney, pancreas, 
skeletal muscle, brain, and leukocyte [12]. These results were subsequently validated by Western 
blot analysis [30]. The fact that, when both MCT1 and MCT2 are expressed in the same tissue, the 
expression pattern is cell-specific, suggests a distinct functional role between these isoforms [46-
49]. Subsequent expression of human MCT2 in Xenopus oocytes revealed its unique biochemical 
feature of facilitating the proton-linked transport of a range of monocarboxylates, especially 
pyruvate, with a considerable high affinity, supporting the previous evidence of an alternative 
biological role [12,44]. Therefore, MCT2 emerges as a high affinity transporter (Table 2), being 
adapted to perform the uptake of monocarboxylates into cells. As a result, MCT2 is found in 
tissues that use lactate as a respiratory fuel, like brain [30,48-51] or cardiac and skeletal muscle 
[30,46], and kidney and liver were lactate is the major gluconeogenic substrate [30,31,46]. As 
MCT1, MCT2 is also found in mitochondria [38,41]. 
 
 
1.1.1.3. MCT4 
In 1998, Price and colleagues subsequently cloned four additional human MCT isoforms [6]. 
These are now referred to as MCT4, MCT5, MCT6 and MCT7, formerly known as MCTs 3-6 [1]. 
When these four new sequences were identified, one of them, was more closely related to chicken 
MCT3 than to MCT1 and MCT2, and, despite the much broader tissue distribution [6], the protein 
was named mammalian MCT3 (SLC16A3) [6]. However, Philp and colleagues subsequently 
cloned rat and mouse MCT3 (SLC16A8). This new MCT3, having an expression confined to the 
retinal pigment epithelium [16,17], as the chicken MCT3 [8,14], suggests that this was the true 
mammalian equivalent to the chicken MCT3. Therefore, the MCT3 identified by Philp and 
colleagues maintained the name, while the four isoforms identified as MCT 3-6 by Price and 
colleagues were renamed MCT 4-7 [1]. 
The human SLC16A3 gene (for review see [52], Appendix II), which encodes for MCT4, is 
located in chromosome 17 (17q25.3), comprises 5 exons and 3 transcripts, with different initiation 
sites but no difference in protein product has been identified (ENSG00000155380, [28]). The 
protein is constituted by 465 residues, corresponding to a molecular weight of 49,469 Da (O15427, 
[29]). 
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Like MCT1, and in opposition to MCT2 and MCT3, MCT4 has a broader distribution, being 
particularly observed in highly glycolytic tissues such as white skeletal muscle fibers, astrocytes, 
and white blood cells [6,13,53]. This led to the hypothesis that MCT4 may be of particular 
importance in tissues that rely on glycolysis to meet their energy demands, producing high 
amounts of lactate that need to be rapidly exported [1,53]. In fact, the kinetic properties of MCT4 
show that this isoform is adapted to the export of lactate [13,45]. MCT4 shows a much lower 
affinity for substrates than MCT1 and MCT2 (Table 2), with  Km values of around 30 mM for L-
lactate [13,45] and 150 mM for pyruvate [45]. 
 
 
1.1.1.4. OTHER MCT ISOFORMS 
Although performing functions different from the family related isoforms MCT1-MCT4, 
other MCT isoforms have been characterised in the last years. SLC18A10 gene encodes for an 
aromatic amino-acid transporter (T-type amino-acid transporter 1, named TAT1 rather than 
MCT10) [54] and has been also recently described, in parallel with MCT8 (SLC16A2) [55], as a 
thyroid hormone transporter [56]. Importantly, mutations in SLC16A2 have been associated with X 
linked severe mental retardation and neurological dysfunction [57-61]. MCT6 (SLC16A5) 
transports bumetanide, but neither L-lactic acid nor L-tryptophan. Butemanide transports is 
sensitive to pH and membrane potential but does not depend on proton gradient [62]. Although the 
substrate for MCT12 (SLC16A12) is still unknown, recent studies suggest a function in the 
establishment and/or maintenance of homeostasis in the eye lens and probably also in the kidney, 
and a mutation SLC16A12 has been associated with development of cataracts [63,64]. 
Furthermore, SLC16A12 has been identified as a possible biomarker for colon, prostate and breast 
carcinoma, due to gene hypermethylation [65]. Finally, a polymorphism in SLC16A9 (encoding 
MCT9) was found to be associated with altered serum uric acid [66], however MCT9 substrate is 
still unknown, as for the remaining members of the family (MCT5, MCT7, MCT11, MCT13 and 
MCT14). 
 
 
1.1.2. ROLE OF MCTS IN METABOLIC HOMEOSTASIS 
As already mentioned, monocarboxylate transporter across the plasma membrane, both 
efflux and uptake, is of extreme importance to maintain the cellular metabolic homeostasis. Rapid 
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efflux of lactic acid across the plasma membrane is essential to all mammalian cells that are 
glycolytic or become glycolytic due to environmental conditions like hypoxia [3]. Lactic acid may 
be exported by MCT1; however, in cells that rely on glycolysis for energy production, MCT4 
appears to be the major isoform. MCT4 has a high Km for pyruvate, so, unlike MCT1, ensures that 
this metabolite is not lost from the cell but reduced to lactic acid, regenerating NAD+, therefore 
allowing glycolysis to continue [5]. Uptake of lactate is also of great importance in tissues such as 
liver and kidney, where lactic acid is transported into the cell to support gluconeogenesis and 
lipogenesis, and in tissues like heart, skeletal muscle and brain, where lactate, together with ketone 
bodies, is used as a major respiratory fuel [1]. Both skeletal muscle and heart express MCT1 to 
meet this role, while in liver, kidney and brain both MCT1 and MCT2 can be used, with the latter 
providing a higher affinity lactate uptake mechanism [1]. Despite the role of MCTs in a wide 
tissue range, no detectable MCT activity is found in the β-cells of the Islets of Langerhans in the 
endocrine pancreas. This phenomenon is also of major physiological relevance, since, by not 
allowing the for pyruvate and lactate, that could enter the citric acid cycle and produce ATP, 
ensures that adequate amounts of insulin are secreted [67]. 
Importantly, lactate is a quantitatively important oxidisable substrate and gluconeogenic 
precursor, being responsible for coordination of intermediary metabolism in diverse tissues. This 
role of lactate as oxidative and gluconeogenic substrate, as well as in cell signalling, is explained 
by the “cell-cell” and “intracellular lactate shuttle” concepts [68-70]. According to the “cell-cell 
lactate shuttle” hypothesis, lactate produced in glycolytic cells will be utilised continuously under 
fully aerobic conditions. This is the case of lactate exchanges between glycolytic astrocytes and 
oxidative neurons [71], between white-glycolytic and red-oxidative fibres within a working 
muscle, and between tissues of net release of lactate and gluconeogenic tissues [72]. In the 
“intracellular lactate shuttle”, mitochondria play a fundamental role in the oxidative catabolism of 
lactate, thanks to a lactate oxidation complex composed of lactate dehydrogenase (LDH) and 
MCTs, which is associated with the electron transport chain [39,40,73]. An “intracellular lactate 
shuttle” is also present in the peroxisome [42]. As lactate is more reduced than pyruvate, lactate 
oxidation to pyruvate (or exchange with pyruvate, and subsequent oxidation) induces a change in 
the cell redox balance. Hence, lactate production in one compartment and its removal from 
another, whether the compartments are at the cellular or tissue level, represents a major signalling 
mechanism [5]. In this regard, MCTs, as responsible for lactate shuttling, play an important role in 
metabolic coordination, linking glycolysis to oxidative metabolism and gluconeogenesis [69], as 
well as providing some harmonisation to the cytosolic redox potential [5]. 
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Two cell-cell lactate shuttles have been described with more detail, one in the brain and the 
other in skeletal muscle, as presented bellow. 
 
 
1.1.2.1. BRAIN LACTATE SHUTTLE 
The classical view of neuroenergetics describes that normal brain is restricted almost 
exclusively to glucose as the substrate for energy production, which is directly delivered to 
neurons via the blood supply [74]. However, recent evidence revealed a more complex metabolic 
pathway, where astrocytes play a role in providing lactate as an additional energy source for 
neurons (for review see [75-77]). 
It was previously shown that lactate produced by muscle during exercise could be used by 
the brain [78-80], as well as that astrocytes have the capacity of producing lactate in the presence 
of normal oxygen levels [81]. With the description of MCT cell-specific expression by both in 
vitro and in vivo studies, new evidence for a complementary metabolism between neurons and 
astrocytes was provided [48-51,82-84]. MCT1 expression is found in astrocytes [48-51,82-84], as 
well as in brain endothelial cells [51,82]. Although firstly reported in astrocytes [82,84], MCT2 is 
exclusively found in neurons [48-51,83], while MCT4 presents a strong expression in the plasma 
membrane of astrocytes [51]. Thus, a mechanism of cell-cell lactate shuttle between astrocytes and 
neurons (Figure 3) is consistent with, on one hand, the fact that neurons contain more 
mitochondria than astrocytes [85], hence neurons are mainly oxidative while astrocytes are mainly 
glycolytic, and, on the other hand, the Km values of each MCT isoform (Table 2). Thus, glycolytic 
astrocytes consume glucose supplied by the blood flow and the resultant lactate is exported 
through MCT1 and MCT4 to the extracellular space; this lactate will be transported by the high 
affinity MCT2 into the oxidative neurons, to be used as a energy substrate for mitochondrial 
oxidation [51,71,75-77]. As mentioned above, MCT activity is not limited to plasma membrane as 
neurons contain a mitochondrial lactate oxidation complex that has the potential to facilitate both 
intracellular and cell-cell lactate shuttles in brain [73]. 
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Figure 3. Schematic illustration of lactate shuttle between astrocytes and neurons (adapted from [51]). 
Abbreviations: GLUT, glucose transporter; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; Ox 
Phos, oxidative phosphorylation; TCA, tricarboxylic acid. 
 
 
1.1.2.2. SKELETAL MUSCLE LACTATE SHUTTLE 
It is known that lactate is released from diverse tissues like skeletal muscle, skin and red 
blood cells, but the high glycolytic rates of skeletal muscle makes this tissue the main producer of 
lactate in the body. This lactate derived from glycolytic skeletal fibers may be consumed by 
adjacent oxidative skeletal fibers or enter the blood flow and be taken up by other tissues such as 
heart and brain to be used as a respiratory fuel, or liver as substrate of gluconeogenesis [1]. MCT1 
and MCT4 are both found in skeletal muscle; however, their relative amounts are dependent on the 
type of muscle fiber. MCT1 expression is prominent in slow twitch (red) muscle fibers [30,53,86-
89], which present oxidative metabolism, and correlates with the concentration of mitochondria 
[86]. In contrast, MCT4 is preferentially expressed in glycolytic fast twitch (white) muscle fibers 
[30,53,87-89]. MCT fiber-specific distribution and differences in MCT affinity for lactate (Table 
2), support the hypothesis of a cell-cell lactate shuttle in skeletal muscle where lactate produced by 
glycolytic fibers is exported by the low affinity MCT4 [13,45], and subsequently imported by 
oxidative fibers through MCT1, which has a higher affinity for lactate than MCT4. The major role 
Chapter 1 General Introduction 
 
 13
 
of MCTs in muscle function is supported by the increase in the density of both MCT isoform, 
especially MCT1, after training periods [90-98]. 
 
 
1.1.3. MCTS IN DISEASE 
Considering the fundamental role of lactate transporters in key metabolic processes like 
glycolysis and gluconeogenesis, it is not surprising that alterations in MCT expression or function 
are associated with physiological dysfunctions. In fact, MCT4 overexpression was reported in a 
patient with a mitochondrial myopathy [99] and MCT4 down-regulation (35% lower expression) 
was described in the vastus lateralis muscle of patients with chronic obstructive pulmonary 
disease [100]. However, these alterations in MCT4 expression appear to be more a consequence 
rather than a cause of the disease. 
In contrast, SLC16A1 mutations associated with exercise-induced hyperinsulinism [101] 
and erythrocyte lactate transporter defect [102], as well as a decrease in SLC16A1 gene 
transcription in inflammatory bowel diseases, have been described and will be further explored 
below. 
 
 
1.1.3.1. EXERCISE-INDUCED HYPERINSULINISM 
Exercise-induced hyperinsulinism is characterised by inappropriate insulin secretion by 
pancreatic β-cells, especially during anaerobic exercise, in response to exogenous catabolic 
metabolites such as lactate and pyruvate [103-105]. As previously mentioned, pancreatic β-cells 
show no MCT activity [67], however, an increase of MCTs in β-cells plasma membrane, will 
allow the entry of pyruvate into the cell and a consequent increase in ATP production and insulin 
secretion. Although no mutations were detected in the coding regions of eight MCT genes in 
earlier studies [104], sequencing of the 5’ UTR and promoter regions of the SLC16A1 gene 
brought new insights on the mechanism for this disease [101]. By studying affected members of a 
Finnish family, segregating autosomal dominant exercise-induced hyperinsulinemic 
hypoglycemia, Otonkoski and colleagues identified two functional alterations in SLC16A1. First, a 
+163G-A transition in exon 1, located within a binding site for nuclear matrix protein-1 (NMP1) 
and predicted to disrupt the binding sites of 2 potential transcriptional repressors (albumin 
negative factor (ANF) and acute myeloid leukemia-1a (AML-1a)), and, second, a 25-bp insertion 
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between nucleotides -23 and -24, introducing additional binding sites for the ubiquitous 
transcription factors simian-virus-40-protein-1 (SP1), upstream stimulatory factor (USF) and 
myeloid zinc finger 1 (MZF1). The first variation leads to a 3.5-fold increase in transcription while 
the second variation leads to a 10-fold increase in transcription. These mutations were not found in 
94 Finnish and German controls, excluding the probability of being polymorphisms [101]. 
 
 
1.1.3.2. ERYTHROCYTE LACTATE TRANSPORTER DEFECT 
In 1986, a rare condition in which apparently healthy patients suffered severe chest pain and 
muscle cramping after vigorous exercise, was associated with an impaired capacity of lactate 
transport by skeletal muscle and red cells [106]. More recently, Merezhinskaya and colleagues 
identified three heterozygous transitions in the SLC16A1 gene, in patients with erythrocyte lactate 
transporter defect. Firstly, a 610A>G transition (resulting in a lys204-to-glu (K204E) substitution 
in a highly conserved residue); secondly, a 1414G>A transition (resulting in a gly472-to-arg 
(G472R) substitution halfway along the cytoplasmic C-terminal chain, in a non-conserved 
residue); and thirdly, a 1470A>T transition (resulting in a glu490-to-asp (E490D), which revealed 
to be a common polymorphism) were identified in patient’s muscle biopsies. Erythrocyte lactate 
clearance in patients with the 2 mutations was 40 to 50% that of normal control values, while for 
patients with the polymorphism erythrocyte lactate clearance was 60 to 65% of mean normal 
[102]. However, heterologous expression of the MCT1 K204E mutant, considered the most 
important alteration due to its location in a conserved residue, failed to support any difference in 
its properties from wild type MCT1 [5]. Thus, it remains unclear if mutations in MCT1 are 
responsible for cryptic exercise intolerance. 
 
 
1.1.3.3. INFLAMMATORY BOWEL DISEASES 
Butyrate, a monocarboxylate commonly referred to as a short-chain fatty acid, is produced in 
the lumen of the colon by microbial fermentation of dietary carbohydrates that escape digestion in 
the small intestine. This monocarboxylate is the major energy source for colonic epithelial cells 
and exerts a variety of effects important to intestinal health and function [107]. Impaired oxidation 
of butyrate has been associated with inflammatory bowel disease, but the mechanism was not 
known [108,109]. Recently, it was observed that inflammation caused down-regulation of MCT1 
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expression in the colonic tissue, the MCT isoform responsible for butyrate uptake in colonic 
epithelial cells [110]. Also, treatment of intestinal epithelial cell lines with pro-inflammatory 
cytokines (interferon-gamma (INF-γ) and tumour necrosis factor-alpha (TNF-α) induced down-
regulation of MCT1 gene transcription, which was associated with a reduction in butyrate uptake 
and subsequent oxidation. Thus, reduction in MCT1-mediated butyrate uptake is the cause of 
butyrate oxidation deficiency in intestinal inflammation [111]. 
 
 
1.1.3.4. CANCER 
It is known that tumour cells are highly glycolytic, producing lactic acid in excess, and both 
biochemical and molecular evidence suggest the up-regulation of MCTs in some tumour cells 
[112]. However, since the role of MCTs in solid tumours is the main subject of this thesis, a more 
detailed review of the state of the art is included latter on. 
 
 
1.1.4. MCT REGULATION 
Reports on MCT expression variations, especially MCT1, have been described in different 
physiological as well as pathological conditions including, among others, MCT up-regulation in 
skeletal muscle in response to training [90-98], down-regulation after muscle denervation [53] and 
in inflammatory bowel diseases [111], changes in MCT expression during development [113-117] 
or substrate-induced MCT1 up-regulation [118-120]. Importantly, regulatory mechanisms vary 
among MCT isoforms, which allow induction of specific isoforms upon different stimuli, adapting 
cells to different energy demands. 
Although the regulatory mechanisms of MCT expression are far from being completely 
unveiled, plenty of evidence indicates that MCTs are regulated at various points up to the 
functional protein, including both transcriptional, and post-transcriptional [31,88,95,119,120] 
regulation that affects protein amounts as well as regulators of transporter activity, like 
chaperone proteins. Further, hormone regulation has also been described for MCTs, as well as 
regulation by signalling pathways like insulin-like growth factor receptor type I (IGF-IR) 
activation, which up-regulates MCT1 [121]. 
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1.1.4.1. TRANSCRIPTIONAL LEVEL 
Transcriptional regulation of genes is a complex mechanism involving intervention of many 
regulatory proteins, including transcription factors, functioning as enhancers or repressors of gene 
transcription [122]. Analysis of SLC16A1 5’-flanking region allowed the identification of putative 
binding site sequences for the transcription factors USF, nuclear factor-kappaB (NF-κB), activated 
protein 1 and 2 (AP1 and AP2) and stimulating protein-1 (Sp1) [27]. In fact, USF1 and USF2 have 
been described as potential repressor proteins for MCT1 [123], NF-κB pathway has been involved 
in the butyrate-induced MCT1 up-regulation [124], while AP2 has been associated to protein 
kinase C (PKC)-dependent stimulation of the SLC16A1 promoter [125]. 
Additionally, lactate-induced increase in MCT1 has been linked to activation of NF-κB and 
nuclear factor erythroid 2 (NF-E2) pathways, as well as cAMP-response element-binding protein 
(CREB) and NF-E2 related factor 2 (Nrf2) transcription factors, the last three elements possessing 
also putative transcription binding sites in the SLC16A1 5’-flanking region [120].  
More recently, the co-activators peroxisome proliferator-activated receptor gamma, co-
activator 1 alpha (PGC-1α) [126] and peroxisome proliferator-activated receptor alpha (PPARα) 
[127,128] have been associated with MCT1, but not with MCT2 and MCT4 up-regulations. In 
fact, promoter analyses of MCT1, MCT2 and MCT4 have shown that the SLC16A1 promoter 
contains two peroxisome proliferator-activated receptor response elements (PPRE) while 
SLC16A7 and SLC16A3 each contain one PPRE [126].  
In expression studies, SLC16A1 was also shown to be activated by c-myc and n-myc proto-
oncogenes [129-131], while the pro-inflammatory cytokines IFN-γ and TNF-α, have also been 
implicated in the transcriptional control of MCT1, by down-regulating SLC16A1 transcription 
[111]. 
Hypoxia conditions, which are known to induce the glycolytic phenotype, are also associated 
with altered expression of MCTs [132-138]. The first report described a tissue-specific change in 
MCT expression after chronic hypoxia, where MCT1 did not change in heart, soleus, or 
gastrocnemius muscles, while MCT4 increased significantly in heart muscle. However, in the 
plantaris muscle, both MCT1 and MCT4 showed a significant decrease after chronic hypoxia 
[132]. A subsequent study suggested that the increase in neuronal, astrocytic and endothelial 
MCT1 expression, observed after permanent occlusion of the left middle cerebral artery, is 
mediated by the hypoxia-inducible factor-1alpha (HIF-1α) [133], the major transcriptional 
regulator of adaptation to hypoxic stress; however, this view was promptly contested by Ullah and 
collaborators who, after performing functional studies with MCT1, MCT2 and MCT4 promoters, 
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showed that only MCT4 promoter was activated by hypoxia and that this response was mediated 
by HIF-1α [135]. Additionally, MCT4, but not MCT1, was shown to be up-regulated by hypoxia 
in human bladder cancer cells [134] and in trophoblast cells [136], and MCT1 and hypoxia were 
described as being mutually exclusive [137]. However, recent evidence describe a hypoxia-
mediated increase in both MCT1 and MCT4 and decrease in MCT2, with MCT1 and MCT4 
change being HIF-1α-dependent [138]. From this, one can conclude that evidence so far, 
especially on MCT1 regulation by hypoxia, is very controversial and more efforts have to be made 
to enlighten the knowledge on MCTs’ regulation by hypoxia. 
 
 
1.1.4.2. POST-TRANSCRIPTIONAL LEVEL 
The relatively long 3’UTR of SLC16A1 (1.6kb), on which initiation factors and regulatory 
proteins interact to enhance or repress translation [139], suggests that MCT1 expression, but not 
MCT2 nor MCT4 which have much shorter 3’UTRs, might also depend on translational regulation 
[1,5]. 
MicroRNAs (miRNAs) are a group of small non-coding RNAs (approximately 22 
nucleotides) that play a critical role in a variety of biological processes, like development, 
differentiation and apoptosis. Mature miRNAs negatively regulate their targets through 
complementary sequence pairing with the 3′ UTR of mRNA targets, inducing transcript 
degradation or translational repression (for review see [140]). One of the most well characterised 
miRNAs in mammalian nervous system is miR-124, which has been described to regulate MCT1; 
miR-124 regulates SLC16A1 through binding to its 3′ UTR and MCT1 protein level is reduced 
after miR-24 transfection [141]. Regulation of SLC16A1 mRNA stability has already been 
described in the context of MCT1 regulation by butyrate [119]. 
 
 
1.1.4.3. TRANSPORTER ACTIVITY LEVEL 
Other factors that may regulate functional expression of MCTs are accessory proteins that 
are involved in trafficking and anchoring of membrane proteins to specific cellular locations. In 
this context, CD147 emerges as the major and better studied regulator of MCT expression. 
CD147, also known as basigin, EMMPRIN, OX-47 and HT7, is a broadly distributed plasma 
membrane glycoprotein discovered in 1982 [142], which belongs to the immunoglobulin 
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superfamily [143]. Originally identified as a tumour surface protein with the ability of inducing 
matrix metalloproteinases, with a critical role in tumour progression, CD147 expression is found 
in cells other than tumour cells where it plays an important role in fetal, neuronal, lymphocyte and 
extracellular matrix development as well as tissue repair (for review see [144,145]). Co-
immunoprecipitation and chemical cross-linking studies showed that CD147 specifically interacts 
with MCT1 (Figure 4) and MCT4, but not MCT2. Also, co-transfection of CD147 allowed active 
expression of MCT1 and MCT4, but not MCT2, in the plasma membrane of MCT-transfected 
cells. When CD147 was not co-transfected, MCT accumulated in a peri-nuclear compartment 
[146]. The close association between CD147 and both MCT1 and MCT4 within the plasma 
membrane was confirmed by co-localisation studies [67,147,148].  
 
 
Figure 4. Monocarboxylate transporter 1 (MCT1) and CD147 predicted interaction (from [146]). This 
interaction is proposed to involve an arginine residue within the transmembrane segment 8 of MCT1 and a glutamic 
acid residue in the transmembrane segment of CD147. 
 
Importantly, subsequent studies showed that, besides being important for MCT membrane 
location [149-153], CD147 has also a role in MCT1, 3 and 4 expression [18,151,153,154] and 
improvement of MCT activity [149,155]. On the other hand, MCT1 and MCT4 have also shown to 
be regulators of CD147 maturation and trafficking to the plasma membrane [150,151]. As 
mentioned above, although also requiring an ancillary protein for proper expression, MCT2 does 
not interact with CD147 nor is influenced by CD147 expression [18,146]. This function is fulfilled 
by another member of the immunoglobulin superfamily, the gp70 protein [156], which, in co-
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immunoprecipitation and co-localisation studies, was found to interact with MCT2 [155]. Gp70 
has also been described as interacting with MCT1 in rat erythrocytes [157]. 
More recently, other players were included in the MCT/CD147 complex. The widely 
distributed transmembrane glycoprotein CD44 and its main ligand, hyaluronan, were implicated in 
the regulation of lactate efflux and membrane localisation of MCTs, in human breast carcinoma 
cells [158]. In fact, CD44 co-immunoprecipitates with MCT1, MCT4 and CD147 and co-localises 
with these proteins in the plasma membrane. Perturbation of endogenous hyaluronan, using 
hyaluronan oligosaccharides, induced intracellular accumulation of CD44, MCT1 and MCT4. 
These observations suggest that constitutive interactions between hyaluronan, CD44 and CD147 
regulate MCT localisation and function of MCT1 and MCT4 [158]. Importantly, a role of CD44 
activation has been described in cell growth control, adhesion, migration, invasion, and 
chemoresistance [159-161], which may count on the contribution of MCTs.  
Additionally, other modulators of transporter activity may directly affect MCT function, 
independently of affecting protein amounts and location, including carbonic anhydrase (CA) II, 
which enhance both MCT1 and MCT4 activity by direct binding [162-164], prion-related protein 
(PrP) [165] and intracellular calcium [166]. 
 
 
1.1.4.4. HORMONAL REGULATION 
Hormonal regulation of MCTs may involve transcriptional and post-transcriptional 
mechanisms. MCTs’ regulation by hormones has been firstly described in 2002, as luminal leptin 
was shown to significantly up-regulate MCT1-mediated butyrate uptake, in Caco2-BBE cell 
monolayers. This increased uptake was achieved through two distinct mechanisms: an increase in 
the intracellular pool of MCT1 protein, with no changes in CD147 amounts, and translocation of 
MCT1/CD147 to the apical membrane of Caco2-BBE cell monolayers [167]. Shortly after, the 
hormones thyroid-stimulating hormone (TSH), noradrenaline, triiodothryonine (T3)  and 
somatostatin were also described as modulators of MCT expression [168-171]. TSH regulates 
MCT1 protein expression in rat thyroid cells, increasing SLC16A1 transcription, and also increases 
CD147 protein levels [170]; noradrenaline induces MCT2, but not MCT1 expression, in mouse 
neurons, at the translational level, with the requirement of an yet unknown transcriptional step 
[168]; MCT4, but not MCT1, is induced by T3 in rat skeletal muscle [169]; and somatostatin 
increases MCT1 association with CD147 at the plasma membrane, with an increase in the apical 
membrane levels of MCT1 protein in parallel to a decrease in the intracellular MCT1 pool [171]. 
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1.1.5. INHIBITION OF MCT ACTIVITY 
Several agents are known to inhibit MCT activity, in an isoform-dependent manner. These 
include classical inhibitors like α-cyano-4-hydroxycinnamate (CHC) or quercetin, inhibitors that 
influence MCT activity in a specific manner like AstraZeneca inhibitors, and molecules that, being 
used in particular contexts, have also been described as inhibitors of MCT activity like cholesterol 
synthesis inhibitors (statins) and non-steroidal anti-inflammatory drugs (NSAIDs) (for review see 
[10]). 
 
 
1.1.5.1. CLASSICAL INHIBITORS 
Identification of MCT inhibitors was achieved during characterisation of MCT1, as the most 
studied MCT isoform. Bulky or aromatic monocarboxylates were among the first inhibitors of 
lactate transport to be identified, which, as substrate analogues, are competitive inhibitors of 
MCT1 [3]. Later on, other types of molecules were identified as inhibiting MCT1 activity, as well 
as the activity of other isoforms.  
Classical reversible inhibitors of MCTs fall into three broad categories (for review, see 
[3,5,11]): 
(1) Bulky or aromatic monocarboxylates like phenyl-pyruvate and CHC. In this 
category, the derivatives of α-cyanocinnamate are the most potent, with Ki values of 50-500 
µM. However, although CHC is often used as a MCT1 specific inhibitor [137,172,173], it 
also inhibits the mitochondrial pyruvate transporter with a Ki<5 µM, as well as the anion 
exchanger 1 (AE1), which is responsible for Cl-/HCO3- membrane exchange [174]. 
(2) Amphiphilic compounds with widely divergent structures like bioflavonoids (e.g. 
phloretin and quercetin) [175] and inhibitors of anion transport (e.g. niflumate). Phloretin 
and quercetin are particularly potent inhibitors of MCT1 but, like the majority of MCT 
classical inhibitors, they also inhibit other membrane transport systems. 
(3) Stilbenedisulphonates (e.g. 4,4'-diisothiocyanostilbene-2,2'-disulphonate (DIDS)). 
These inhibitors are some of the most effective MCT inhibitors with Ki<40 µM, however, 
with much lower affinity than for AE1. 
Additionally, miscellaneous inhibitors including thiol reagents, such as the organomercurial 
thiol reagent p-chloromercuribenzene sulphonate (pCMBS), and amino reagents (e.g. pyridoxal 
phosphate and phenylglyoxal) irreversibly inhibit MCTs (for review, see [3,5,11]). 
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Importantly, these inhibitors have different affinities among MCT isoforms. MCT2 is more 
sensitive to CHC, DIDS and phloretin than MCT1 [44], but is not sensitive to pCMBS, due to the 
different ancillary protein [155]; MCT3 is insensitive to CHC, pCMBS and phloretin [176]; and 
MCT4, although also sensitive to CHC, DIDS and pCMBS, inhibition is achieved with a much 
lower affinity, which is in accordance with the low affinity characteristics of this transporter 
[13,45]. 
 
 
1.1.5.2. SPECIFIC INHIBITORS 
As mentioned above, none of the MCT classical inhibitors is either MCT specific or MCT 
isoform specific. Therefore, to investigate the role of MCT in cellular function, MCT specific 
inhibitors should be used. 
T cell activation is dependent on glycolysis and this leads to a high rate of lactate 
production, due to a higher energetic demand during proliferation and cytokine production [177]. 
In the immunological context this may be of great importance, as inhibition of T cell activation has 
therapeutic implications in immunosuppressive therapy. It was in this perspective that specific 
MCT1 inhibitors arose, when MCT1 was identified as the target for newly developed 
AstraZeneca immunomodulatory compounds, that potently inhibit human and rat T lymphocyte 
activation [178,179]. These compounds have shown promising results in allograft rejection both in 
mouse and rat [180,181], having also been used in the context of the astrocytes-neuron lactate 
shuttle, where inhibition of both MCT1 and MCT2 was achieved [182]. In fact, some of these 
compounds appear to be MCT isoform specific [178], while others, although binding with higher 
affinity to MCT1, also bind to other MCT isoforms [182]. 
 
 
1.1.5.3. OTHER INHIBITORS 
Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been 
known to inhibit glycolysis in cancer cells. Although this action was originally attributed to 
hexokinase inhibition [183], further studies revealed that lonidamine inhibits lactate efflux from 
cancer cells [184,185], through inhibition of MCT1 and MCT4 [130]. Actually, despite a lack of 
knowledge of its precise mechanism of action, lonidamine has been effective in clinical trials 
against various tumours, especially as a sensitizer to other chemotherapies [186]. 
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Statins are 3-hydroxyl-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, 
which are used as safe and effective drugs for managing hypercholesterolemia [187]. Lipophilic 
compounds, such as fluvastatin, atorvastatin, lovastatin acid, simvastatin acid and cerivastatin, 
have monocarboxylate structures within the compounds, making these molecules putative MCT 
substrates. Actually, these statins have been shown to be MCT4 substrates and, therefore, 
inhibitors of lactate and other substrates’ transport [188-190]. The interaction of simvastatin with 
MCT4 accounts for the simvastatin-induced muscular toxicity, observed in MCT4 expressing 
skeletal muscle but not in MCT1 expressing heart muscle [191]. 
Although apparently being transported through a transport system other than MCT in 
trophoblast BeWo cells [192], NSAIDs have been described as partially transported by MCT1 in 
Caco-2 cells [193], and also described as potent inhibitors of lactate transport [188,189,192]. 
 
 
1.2. ROLE OF MCT IN CANCER CELL METABOLIC PHENOTYPE 
The role of MCTs in physiological homeostasis is widely accepted and described in detail in 
some tissues. Also, as mentioned previously, MCT has also a role in disease. However, in what 
concerns tumour biology, a lot of work is needed to shed some light in that area. Even though, if 
one looks at the microenvironmental scenario and molecular events that occurs in carcinogenesis, 
it is possible to anticipate an important contribution of MCTs in the progression to malignancy. 
 
 
1.2.1. CANCER HALLMARKS: CONTRIBUTION OF MICROENVIRONMENT  
Over the last years, much attention has been given to the genetic and epigenetic alterations 
occurring in cancer development, which ultimately leads to emergence of invasive cancer. In fact, 
conceptual models of epithelial carcinogenesis are typically based on Darwinian dynamics and 
depict a sequence of heritable changes, as described in the genetic model of colorectal 
tumourigenesis described by Fearon and Volgestein [194], that give rise to a population of cells 
possessing the hallmarks of invasive cancer (Figure 5) [195]. Therefore, in general, cancer 
evolution consists in accumulation of alterations in oncogenes, proto-oncogenes and tumour 
suppressor genes that will increase growth-promotion signals and decrease growth inhibitors 
[196]. However, this classical view does not account for the other component of Darwinian 
dynamics, where the environment exerts a selection force that will only allow the emergence of 
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successful adaptations. In this context, the specific changes that occur in tumour 
microenvironment are emerging as key components in carcinogenesis.  
 
 
Figure 5. The hallmarks of cancer. Although through various mechanistic strategies, all cancers have acquired 
the same set of functional capabilities during their development (from [195]). 
 
 
1.2.1.1. THE WARBURG EFFECT 
More than half a century ago, Otto Warburg demonstrated that cancer cells rapidly convert 
the majority of glucose into lactate, even in the presence of sufficient oxygen to support 
mitochondrial oxidative phosphorylation [197]. This phenomenon is presently known as “aerobic 
glycolysis” or “Warburg effect” (Figure 6). Although Warburg’s hypothesis that impaired 
mitochondrial metabolism underlies the high rates of glycolysis has proven incorrect [198-200], 
the original observation of increased glycolysis in tumours has been confirmed repeatedly. In fact, 
this increased glucose uptake by cancer cells is the rationale behind the whole-body non-invasive 
18F-fluorodeoxyglucose positron emission tomography (FdG-PET) technique. This widespread 
clinical application is used for diagnosis, initial staging, restaging, prediction, monitoring of 
treatment response and surveillance in a variety of cancers [201].  
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Figure 6. Schematic representation of the main differences between oxidative phosphorylation, anaerobic 
glycolysis and aerobic glycolysis (adapted from [202]). 
 
Aerobic glycolysis, where metabolism of glucose to lactate generates only around 4 ATP per 
molecule of glucose (Figure 6), is a much less efficient energetic pathway than mitochondrial 
oxidative phosphorylation, where complete oxidation of one molecule of glucose through yields 
around 30 ATP [203]. Additionally, the metabolic products of glycolysis, including lactic acid and 
H+, cause a consistent acidification of the extracellular space [204-207], which might result in 
cellular toxicity. Therefore, why do cancer cells engage into the glycolytic phenotype, where only 
a fraction of the energy is obtained from glucose and possibly harmful products are produced? At 
first glance, cancer cells have no proliferative advantage in having a glycolytic metabolism, 
however, as discussed below, this apparent deleterious feature is, in fact, the key cellular trait that 
allows selection for cancer cells [208]. 
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1.2.1.2. MICROENVIRONMENTAL HYPOXIA AND ACIDOSIS: THE EMERGENCE OF THE HYPER-
GLYCOLYTIC ACID-RESISTANT PHENOTYPE 
Epithelial cells and the underlying stroma are physically separated by a basement membrane. 
As carcinogenesis occurs, the epithelial cell layer becomes increasingly thicker, driving cells 
towards a lumen that is further away from blood supply, as blood vessels are confined to the 
stroma (Figure 7). Therefore, early carcinogenesis and development of the malignant phenotype 
occur in an avascular environment, and cancer cells become dependent on glucose and oxygen 
diffusion through blood vessels and basement membrane to fulfil the major metabolic demands 
[208,209]. The first limiting substrate for cell growth is oxygen, with hypoxia expected at 
distances between 100 to 150 µm from the vessel wall [210-212], while glucose diffusion 
distances are substantially larger [196,211,213]. 
 
 
Figure 7. Model for cell-environment interactions in carcinogenesis (adapted from [208]). Cell colours 
represent different cell types: grey for normal epithelial cells, pink for hyper-proliferative cells, blue for hypoxic cells, 
green for glycolytic cells and yellow for motile cells. Light orange nuclei represent one mutation while dark orange 
nuclei represent more than one mutation. Blebbing membranes show apoptotic cells. Abbreviations: HIF-1α, hypoxia-
inducible factor 1alpha; VEGF, vascular endothelial growth factor. 
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Hence, if early hyperplastic lesions develop further than a few layers beyond the basement 
membrane, regional development of hypoxia will occur, limiting cell growth. This intermittent 
hypoxia will promote selection for cells with anaerobic glycolysis constitutively up-regulated, 
allowing further cell growth [208,209,214]. However, how could the cell benefit from entering an 
energetically less efficient metabolism? Besides being a successful adaptation to hypoxic 
microenvironment, anaerobic glycolysis allows cancer cells to use the most abundant extracellular 
nutrient, glucose, to produce ATP, which, thanks to the high glycolytic rates (more than 30-fold 
higher than normal cells [215]), can easily exceed the ATP yield of oxidative phosphorylation 
[216]. Additionally, excess pyruvate provides a source for anabolic substrates essential for 
biosynthetic pathways, including ribose sugars for nucleotides, glycerol and citrate for lipids, and 
nonessential aminoacids [216,217]. Importantly, aerobic glycolysis may protect DNA from 
damage by oxygen radicals produced by oxidative phosphorylation [218]. 
The next limiting step was originally thought to be the glucose diffusion limit [208], 
however, new evidence demonstrates that the microenvironment acidosis created by the glycolytic 
phenotype is responsible for further selection, in this case, of an acid-resistant phenotype 
[196,209,214]. Since prolonged exposure to an acidic microenvironment typically results in 
necrosis or apoptosis [219,220], additional adaptations of cancer cells will include resistance to 
acid-induced apoptosis and up-regulation of membrane pH regulators [208]. This potential 
disadvantage of hyper-glycolytic phenotype, in fact provides further competitive advantage [208] 
since, on one hand, the significant decrease in local extracellular pH generates a microenvironment 
that is fatal to the surrounding normal cells, but harmless to cancer cells and, on the other hand, 
facilitates cancer cell invasion behaviour [221-224] through the acid-induced degradation of the 
extracellular matrix [225,226] and angiogenesis [227,228]. 
Therefore, adaptation to hypoxia and acidosis will force the emergence of an adaptive 
phenotype with constitutive up-regulation of glycolysis and resistance to acid-induced toxicity, 
that will invade the normoxic regions and ultimately breach the basement membrane towards 
invasion (Figure 7) [196]. Hence, aerobic glycolysis, a common feature in primary tumours, is 
pointed as an additional hallmark of cancer, as it is required for evolution of invasive human 
cancers (Figure 8) [208,229]. 
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Figure 8. The hallmarks of cancer (adapted from [229]). The eight rectangular icons represent the hallmarks of 
cancer, while the three circular icons indicate three important components of the physiological microenvironment that 
must be overcome in cancer progression. Abbreviation: CiS, carcinoma in situ. 
 
 
1.2.1.3. MOLECULAR MECHANISMS: CONTRIBUTION OF HIF-1α 
As mentioned above, the glycolytic phenotype arises as an adaptation to the hypoxic 
environment. It is widely known that the major regulator of adaptation to hypoxic stress is the 
transcriptional factor HIF-1α, which has been widely associated with cancer progression [230-
235]. In fact, many enzymes from the glycolytic pathway like the glucose transporter 1 (GLUT1) 
[236,237], lactate dehydrogenase A (LDH-A) [238], pyruvate dehydrogenase kinase 1 (PDK1) 
[239,240], among others [235,241,242], are HIF-1α targets (Figure 9). With the increase in 
glucose uptake into the cell, due to higher amounts of glucose transporters, as well as clearance of 
pyruvate by rapid conversion of pyruvate into lactate through LDH-A (with regeneration of 
NAD+), high glycolytic rates can be maintained. Actually, metastatic cancer cells expressing high 
levels of HIF-1α, are highly glycolytic, even under normal oxygen conditions, whereas non-
metastatic cancer cells consume low amounts of glucose and have low HIF-1α levels [243]. 
Additionally, by up-regulating PDK1 (which inactivates the tricarboxylic acid (TCA) cycle 
enzyme pyruvate dehydrogenase (PDH)), HIF-1α will also contribute to suppress the 
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mitochondrial metabolism, rescuing cells from ROS generation and hypoxia-induced apoptosis 
[239,240]. Besides contributing to the constitutive glycolytic metabolism, HIF-1α also contributes 
to the acid-resistant phenotype, by up-regulating, at least, two important pH regulators, MCT4 
[135,138] and CAIX [244-246]. As mentioned above, by co-transporting lactate with H+, MCT4 
has an important function as pH regulator. In fact, MCT4 will not only be important for the acid-
resistant phenotype, but also for the hyper-glycolytic phenotype in the way that, by exporting 
newly formed lactate, will allow continuous conversion of pyruvate to lactate and, therefore, 
continuous aerobic glycolysis. CAIX catalyses the extracellular hydration of CO2 into HCO3- and 
H+. Then, HCO3- enters the cell through AE1 where, in combination with the accumulating H+ 
derived from the glycolytic metabolism, forms CO2 and H2O, that will exit the cell by diffusion, 
causing trapping of the H+ in the extracellular milieu [174,247]. Therefore, HIF-1α plays a major 
role in inducing the hyper-glycolytic acid-resistant phenotype. 
 
 
Figure 9. Major signalling network to regulate metabolism in proliferating cells (from [216]). Abbreviations: 
3-PG, 3-phosphoglycerate; AAs, aminoacids; Ac-CoA, acetyl-coenzyme A; FH, fumarate hydratase; GF, growth 
factor; glc, glucose; glc-6-P, glucose-6-phosphate; GLUT1, glucose transporter 1; HIF-1α, hypoxia-inducible factor-
1alpha; Lac, lactate; LDH-A, lactate dehydrogenase A; mTOR, mammalian target of rapamycin; ROS, reactive 
oxygen species; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1; PI3K, phosphatidylinositol 
3-kinase; PTEN, phosphatase and tensin homolog; Pyr, pyruvate; SDH, succinate dehydrogenase; TCA, tricarboxylic 
acid; TSC, tuberous sclerosis complex; VHL, von Hippel-Lindau. 
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Additionally, constitutive up-regulation of the glycolytic phenotype may occur through 
oncogene activation or tumour suppressor inactivation. Among others, AKT [248-250] and c-myc 
[251-253] oncogenes have been described as activating aerobic glycolysis (Figure 9), the last one 
in cooperation with HIF-1α [254-256]. Loss of the tumour suppressor p53 has also been 
implicated in the glycolytic phenotype [257,258]. 
 
 
1.2.2. ARE MCTS SUITABLE TARGETS FOR CANCER THERAPY? 
The frequency and severity of tumour hypoxia and its association with malignant 
progression make the hypoxia-induced metabolic adaptations promising targets for cancer therapy 
[259]. Actually, the development of treatments that target tumour metabolism is receiving renewed 
attention, with several potential drugs targeting metabolic pathways currently in clinical trials 
(Table 3, for review see [260]). However, MCTs are not yet included in this list of metabolic 
targets for cancer therapy. 
 
Table 3. Compounds targeting tumour glycolysis metabolism (adapted from [260]).  
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As mentioned, the acid-resistant phenotype is essential for cancer cell survival. Hence, 
different pH regulating systems are present in the plasma membrane of cancer cells (Figure 10), 
including the Na+/H+ exchanger 1 (NHE1), CAIX and AE1. Intracellular H+ ions are primarily 
extruded by NHE1, while lactic acid together with H+ are exported by MCTs, in particular MCT1 
and MCT4. CAIX, as already described, works in collaboration with AE1 to trap H+ ions in the 
extracellular space (for review see [261]). Although MCTs are not the major H+ transporters, they 
perform a double role in the adaptation to hypoxia: export of lactate, essential to the hyper-
glycolytic phenotype, and pH regulation, important to the acid-resistant phenotype. Thus, MCTs 
appear as very promising targets in cancer cells with hyper-glycolytic acid-resistant phenotype. 
 
 
Figure 10. Therapeutic targets for manipulation of metabolism in malignant tumours (from [260]). 
Abbreviations: 5-FU, 5-fluorouracil; αKG, alpha-ketoglutarate; ACLY, ATP citrate lyase; CA, carbonic anhydrase; 
CINN, α-cyano-4-hydroxycinnamate; DCA, dichloroacetate; FASN, fatty acid synthase; G6P, glucose-6-phosphate; 
Glut, glucose transporter; HK, hexokinase; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; LDH, lactate 
dehydrogenase; Mal, malate; MCT, monocarboxylate transporter; NHE1, Na+/H+ exchanger 1; OAA, oxaloacetate; 
PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PEP, phosphoenol pyruvate; PK, pyruvate 
kinase; R5P, ribose 5-phosphate; TCA, tricarboxylic acid. 
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1.2.2.1. LACTATE AS A CONTRIBUTOR FOR THE MALIGNANT PHENOTYPE 
As mentioned before, tumour acidity is associated with cancer cell invasion behaviour, i.e. 
increased migration, invasion and metastases. Additionally, cancer acidosis is also associated with 
mutagenesis/clastogenesis, radioresistance and resistance to anthracyclines [208]. It has long been 
known that lactic acid is the main source of tumour acidity, as hyperglycemia acidifies the tumour 
microenvironment [204,262,263]. Although lactate has been proven to cause acidification of the 
extracellular milieu [264-268], other sources of acidity, like carbon dioxide, which were described 
later on, probably have higher contribution to acidification of tumour microenvironment [264-
267]. Although sharing its role as tumour acidifier, lactate has other properties which contribute 
modestly to the malignant behaviour of cancer cells. As mentioned above, T cell activation is 
dependent on high rates of glycolysis, therefore, dependent on a rapid efflux of lactate from T cells 
[177]. However, if extracellular concentration of lactate is high, lactate efflux from T cells will be 
inhibited. This is the case of the tumour micromilieu and, as a consequence, T cell metabolism and 
function will be disturbed, decreasing the immune response against tumour cells [268]. Also, 
evidence shows that both lactate and pyruvate regulate hypoxia-inducible gene expression, 
independently from hypoxia, by stimulating the accumulation of HIF-1α [269]. This indicates that, 
lactate, per se, stimulates the hyper-glycolytic phenotype, providing a positive feed-back. 
Moreover, exogenous lactate was demonstrated to increase cellular motility [270], vascular 
endothelial growth factor (VEGF), the major angiogenic factor [271-273], as well as hyaluronan 
and its receptor CD44, which are molecules involved in the process of cancer invasion and 
metastisation [274,275]. Altogether, this evidence shows the various biological activities of lactate 
that can enhance the malignant phenotype of tumour cells, contributing to the association of high 
tumour lactate concentrations with incidence of metastases [276-279], tumour recurrence, patient 
survival [278,279] and radioresistance [280]. 
Although glucose is the major source of lactate in most solid tumours, it is important to note 
that other cancer pathways rather than glycolysis can culminate in the production of lactate. This is 
the case of glutaminolysis and serinolysis [281-284]. Nevertheless, lactate will always be a 
metabolic end-product, either cancer cells use glycolysis or other energetic pathways for energy 
and biomass production. 
As already mentioned, lactate, besides being an end-product of different metabolic 
pathways, may also be a substrate for oxidative phosphorylation. Actually, as described in skeletal 
muscle and in brain, a cell-cell lactate shuttle as been proposed for cancer cells. Therefore, a 
metabolic symbiosis between glycolytic and oxidative cancer cells was described, in which the 
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peripheral and oxygenated oxidative cells consume the lactate produced by the central and less 
oxygenated glycolytic cells [137]. As discussed below, this might have important therapeutical 
implications. 
 
 
1.2.2.2. MCT EXPRESSION IN HUMAN SOLID TUMOURS 
Giving the increased lactate and acid production by cancer cells, one can anticipate that 
MCTs, especially MCT1 and MCT4, as the transporters responsible for lactate efflux from cells, 
with a pH regulation function, are increased in tumours. Also, as already mentioned, MCTs are 
regulated by HIF-1α [133,135,138] and c-myc oncogene [129,131], which are key molecular 
players in the metabolic adaptations in cancer progression. Although less explored than other 
proteins involved in the glycolytic pathway or even than other pH regulators, reports on the 
importance of MCTs in cancer are becoming more frequent with years. 
The first report on MCT expression in human tumour samples described a decrease of 
MCT1 expression (by Western blot) in colonic transition from normality to malignancy [110], 
which was further supported by a larger study analysing MCT1, MCT2, and MCT4 expressions by 
Northern blot, Western blot and, only for MCT1, immunohistochemistry, in 25 healthy colon 
samples, 20 adenomas and 30 carcinomas. MCT1 decrease was confirmed, while MCT2 and 
MCT4 protein expression was not detected, despite mRNA expression of MCT4 [285]. However, 
evidence from Koukourakis and collaborators [286] showed a clear and strong membranous 
expression of MCT1 in cancer cells in all the 70 colorectal carcinomas analysed but not in the 20 
normal colonic samples. These contradictory results are probably due to antibody specificity, with 
special attention to the fact that the first immunohistochemical study failed to show MCT1 
expression in the plasma membrane of cancer cells, which is essential for plasma membrane 
lactate efflux. Koukourakis and collaborators also found MCT1 expression in tumour-associated 
fibroblasts, favouring absorption of the accumulating lactate from the extracellular matrix, to be 
used as energy source, as well as lack of endothelial MCT1, to avoid lactate absorption and 
vascular destruction by acidosis. Additionally, MCT2 was strongly expressed in the cytoplasm of 
cancer cells and tumour-associated fibroblasts, indicating a possible role of MCT2 in the 
mitochondrial uptake of pyruvate. Finally, MCT4 was weakly expressed in the tumour 
micromilieu, suggesting a minimal role in the metabolic intratumoural communication. Besides 
MCTs, other relevant metabolic proteins were studied and a model of complementary metabolism 
between cancer cells, tumour-associated fibroblasts and vessels is proposed (Figure 11) [286]. A 
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similar metabolic cooperation between lung cancer cells and tumour-associated stroma was 
described, where overexpression of MCT1 was found in all tumours examined, with MCT2 and 
MCT4 also expressed in cancer cells. Tumour-associated stroma weakly expressed MCTs while 
no expression of MCTs was found in normal lung [287]. MCT1, in association with its chaperone 
CD147, was also described in alveolar soft part sarcoma [148]. 
 
 
Figure 11. Model of metabolic cooperation between cancer cells, tumour-associated fibroblasts and endothelial 
cells (from [286]). Step 1, glucose (G) reaches cancer cells through the tumour-associated vasculature followed by 
absorption by glucose transporter 1 (GLUT1). Glucose absorption by stromal fibroblasts is much lower, while, 
endothelial cells absorb glucose directly from the blood. Step 2, in cancer cells, glucose is transformed into pyruvate 
(P) and subsequently to lactate (L). Cancer cells may, therefore, have minimal requirements for oxygen so that oxygen 
use is reduced. Step 3, the high concentrations of lactate in the cancer cell cytoplasm is rapidly extruded to the 
extracellular matrix through the intense activity of the monocarboxylate transporter 1 (MCT1). Step 4, the high 
expression of MCT1 in stromal fibroblasts results, under low pH conditions, in intense absorption of lactate that is 
eventually used as a fuel to acquire energy after its oxidation back to pyruvate. Aerobic metabolism is, therefore, the 
main source of energy acquired by fibroblasts; thus, the oxygen diffused from the tumour-associated vessels is used 
mainly by the stroma and not by cancer cells. Step 5, excess pyruvate production within fibroblasts creates a gradient 
between cytoplasm and extracellular matrix, with MCT1 exporting pyruvate that can be used subsequently by cancer 
cells as a fuel, ending again in lactate production. Abbreviations: LDH, lactate dehydrogenase; m, mitochondria; PDH, 
pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase. 
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In neoplastic human tissues of the central nervous system, strong expression of MCT1 was 
found in ependymomas, hemangioblastomas and high grade glial neoplasms (anaplastic 
astrocytomas and glioblastoma multiforme (GBM)), whereas low-grade glial neoplasms 
(oligodendrogliomas and astrocytomas) were either negative or showed weak MCT1 expression. 
MCT1 expression was also present in microvessels and ependymocytes of normal tissues [288]. 
Additionally, Western blot analysis in total protein extracts from normal brain and primary brain 
tumours (GBMs) demonstrated that normal brain predominantly expressed MCT3, whereas MCT1 
and MCT2 were the major isoforms present in GBM tumours. MCT4 was not detected in any of 
the tumour tissues [289]. A more recent study on a sympathetic nervous system tumour, 
neuroblastoma, showed, by mRNA quantification, that MCT1 expression in this type of tumour is 
also high and is associated with age >1 year at diagnosis, stage 4 disease, unfavourable Shimada 
histopathology, DNA diploid index, n-myc amplification and high-risk clinical group (Children’s 
Oncology Group criteria) [130]. 
As expected, a general up-regulation of MCTs, especially MCT1, is found in solid tumours. 
However, evidence for MCT down-regulation is not only observed in colon carcinoma [110,285]. 
In fact, silencing of SLC16A1 by gene promoter hypermethylation in 4 of 20 breast cases (20%) is 
suggested, however, the resultant decrease of mRNA and protein were not demonstrated [290]. 
 
 
1.2.2.3. MCT TARGETING IN TUMOUR MODELS 
Inhibition of MCTs will have a direct effect on monocarboxylate transport, as well as on pH 
homeostasis, therefore having an important effect on cancer cell viability. Also, considering the 
above mentioned cell-cell lactate shuttle in cancer cells, where MCT1 has a crucial role as the 
gatekeeper of metabolic symbiosis of cancer cells, by importing lactate into oxidative cells, 
targeting of MCT1 will have important implications in cancer homeostasis (Figure 12). Blocking 
the capacity of aerobic cells to use lactate will force them to use glucose, depriving hypoxic 
tumour cells of adequate amounts of glucose and, therefore, favouring hypoxic cell death. 
Radiotherapy is then particularly suited to eliminate the remaining oxygenated cells in the vicinity 
of blood cells [137]. Finally, taking into account all the biological activities of lactate that can 
enhance the malignant phenotype, together with the fact that MCTs’ up-regulation has been 
described in some tumours, MCT inhibition may be a useful therapeutic approach in cancer, 
counteracting lactate effects and, therefore, among others, increase the immune response against 
tumour cells and decrease migration capacity of cells. 
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Figure 12. Model for therapeutic targeting of lactate-based symbiosis in tumours (from [137]). Hypoxic 
tumour cells depend on glucose and glycolysis to produce energy. Lactate, the end-product of glycolysis, diffuses 
along its concentration gradient towards blood vessels. In contrast, oxygenated tumour cells import lactate through 
monocarboxylate transporter 1 (MCT1) and oxidise it to produce energy. In the respiration process, lactate is preferred 
over glucose. As a consequence, glucose freely diffuses through the oxygenated tumour cells to fuel glycolysis of 
distant, hypoxic tumour cells. This metabolic symbiosis can be disrupted by MCT1 inhibition. Upon MCT1 inhibition, 
oxidative tumour cells switch from lactate oxidation to glycolysis, thereby preventing adequate glucose delivery to 
glycolytic cells, which die from glucose starvation. This glycolytic switch is associated with a decrease in oxygen 
consumption of surviving tumour cells, which is responsible for increased tumour pO2. MCT1 inhibition is thus a 
potent antitumour strategy that indirectly eradicates hypoxic/glycolytic tumour cells. Abbreviation: GLUT, glucose 
transporter. 
 
Actually, it was demonstrated that MCT1 inhibition decreases intracellular pH 
[130,137,172], leads to in vitro cell death [130,137,172,173,289] and enhances cancer cell 
radiosensitivity [173]. Additionally, silencing of MCT4 results in decreased cancer cell migration 
[151], by mechanisms that also involve interaction of MCT4 with β1-integrin [291]. Importantly, 
promising results using in vivo models have also been reported, where administration of CHC 
retarded tumour growth and rendered tumour cells sensitive to radiation [137]. 
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Over the last few years, different approaches have been used to disrupt the function of 
tumour MCTs, including the already mentioned CHC [130,137,172,173] and lonidamine [130]. 
Additionally, since these inhibitors have also other targets rather than MCTs, small-interfering 
RNAs (siRNAs) have also been used to inhibit MCT activity in a more direct manner 
[130,137,289]. The use of MCT1 specific inhibitors designed by AstraZeneca may also be an 
effective strategy to block MCT1 tumour activity both in vitro and in vivo and, perhaps, may also 
be adequate compounds to use in the clinical context. As CD147 has an important role in MCT 
trafficking to the plasma membrane and MCT activity [18,146,149-155], indirect MCT inhibition 
through CD147 has also proven to have the ability of reducing the malignant potential of cancer 
cells [152-154]. 
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2.1. CHAPTER OVERVIEW 
It is known that butyrate plays an important role in the maintenance of colonic homeostasis. 
This short-chain fatty acid is implicated in the regulation of colonic mucosa growth and in vitro 
cell proliferation and differentiation, involving the activation of several differentiation-specific 
genes. Additionally, butyrate has a potent effect in inhibiting inflammation and carcinogenesis (for 
review see [1]). Transport of butyrate into the colonic epithelial cells is mostly done through 
MCT1 [2], conferring to this MCT isoform a major role in colonic homeostasis. 
The multistep colon carcinogenesis is generally known to result from the accumulation of 
molecular genetic alterations, mainly activation of oncogenes; inactivation of tumour-suppressor 
genes; and abnormalities in genes involved in DNA mismatch repair [3]. However, other 
alterations have been described that point to an important metabolic switch from butyrate β-
oxidation to glycolysis [4], including up-regulation of GLUT1 [5,6] and production of high levels 
of glycolytic metabolites, such as lactate [7]. 
As mentioned previously, data on MCT1 expression in colorectal cancer is quite 
controversial with reports showing a decrease of MCT1 in the transition from normality to 
malignancy [5,8], as well as absence of MCT2 and MCT4 expression in colon carcinoma [5], 
while another describes an increase of MCT1 in colorectal carcinoma, as well as a strong 
expression of MCT2 in cancer cells cytoplasm, when comparing to normal colonic tissues [6]. In 
this regard, the evaluation of MCT1, as well as other MCT isoforms in colorectal carcinoma 
compared to non-neoplastic tissues, will give an important contribution to the understanding of the 
adaptations that occur toward the metabolic switch occurring in colon carcinogenesis. 
In this chapter, MCT1, MCT2 and MCT4 expressions were evaluated in a comprehensive 
series of 126 colorectal samples. In this study, already published in an international scientific 
periodical with referees, a significant increase of MCT1, MCT2 and MCT4 expressions was 
observed. Importantly, while the increase in MCT1 and MCT4 was associated with an increase in 
cancer cell plasma membrane expression, in the case of MCT2, the increase in cytoplasm 
expression was accompanied by a loss of plasma membrane expression, pointing to a possible role 
of MCT2 in an intracellular organelle, possibly mitochondria. Importantly, analysis of MCT 
expression in regard to the clinic-pathological parameters showed associations of MCT1 plasma 
membrane expression with vascular invasion as well as a borderline association of MCT4 overall 
expression with smaller tumours, which will need further confirmation. 
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2.2. PUBLISHED RESULTS 
The results presented in this chapter were published in an international scientific periodical 
with referees: 
Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues 
M, Alves VA, Schmitt F, Baltazar F (2008). Increased expression of monocarboxylate transporters 
1, 2 and 4 in colorectal carcinomas. Virchows Arch 452:139-146. 
 
 
 
 
 
 
 
 
 
The results presented in this chapter were also presented as oral communication in the following 
national scientific meeting: 
XLI Congresso Sociedade Portuguesa de Microscopia 2006, Braga, Portugal. Pinheiro C, Longatto 
A, Ferreira L, Scapulatempo C, Alves VAF, Milanezi F, Schmitt F, Baltazar F. Characterization of 
monocarboxylate transporters in colorectal carcinomas. 
 
Additionally, these results were presented as poster in the following international scientific 
meetings: 
Twenty-seventh International Congress of the International-Academy-of-Pathology, 2008, Athens, 
Greece. Scapulatempo C, Longatto A, Simoes K, Pinheiro C, Schmitt F , Baltazar F, Alves V. Apoptosis 
detected by cleaved cytokeratin 18 (M30) immunohistochemistry in colorectal cancer is related to acidic 
tumoral microenviroment. Abstract published in conference proceedings (Histopathology 53 (Sp. Iss. 
1):159-160); 
Twenty-first European Congress of Pathology, 2007, Istambul, Turkey. Pinheiro C, Longatto-Filho 
A, Ferreira L, Scapulatempo C, Alves VAF, Pellerin L, Schmitt F, Baltazar F. Altered expression of 
monocarboxylate transporters 1, 2 and 4 in colorectal carcinomas. Abstract published in conference 
proceedings (Virchows Arch 451:325); 
Tenth Cancer Research UK Beatson International Cancer Conference, 2007, Glasgow, United 
Kingdom. Pinheiro C, Longatto-Filho A, Ferreira L, Scapulatempo C, Pellerin L, Alves VAF, Schmitt F, 
Baltazar F. Monocarboxylate transporters as new targets for colorectal cancer therapy? 
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3.1. CHAPTER OVERVIEW 
Cervical carcinogenesis is probably the best defined carcinogenic mechanism. In fact, it is 
widely accepted that cervical carcinogenesis is triggered by human papillomavirus (HPV) 
infection, which, present in virtually all cervical tumours, is a necessary cause for cervical cancer 
development [1]. Although the glycolytic metabolism has been associated with cervical tumours 
since long time ago [2,3], it was recently demonstrated that HPV-16 E7 oncogene is associated 
with increased glutaminolysis [4] as well as an increase in transketolase-like enzyme 1, a crucial 
enzyme of the non-oxidative pathway of the pentose phosphate pathway [5,6]. However, although 
the relevance of glycolysis in cervical neoplasia is still unknown, lactate, which can result from, 
besides glycolysis, glutaminolysis and other metabolic pathways [4,7-9], continues being a 
metabolic end-product that needs to be transported out of the cell. 
Despite the important role of lactate in cervical cancer, where high lactate levels have been 
described as predictor of poor prognosis [10,11], expression of MCTs has not yet been described 
in human cervical carcinoma samples. 
In the following studies, published in international scientific periodicals with referees, the 
expressions of MCT1, MCT2 and MCT4, as well as the MCT1/MCT4 chaperone CD147, were 
assessed in a large series of cervical lesions, which included 29 chronic cervicitis (non-neoplastic), 
30 low-grade squamous intraepithelial lesions, 32 high-grade squamous intraepithelial lesions, 49 
squamous cell carcinomas, 51 adenocarcinomas, and 30 adenosquamous carcinomas of the uterine 
cervix. In the first study, a significant increase in overall and plasma membrane expression of 
MCT1 and MCT4 was observed from pre-invasive to invasive squamous lesions and from normal 
glandular epithelium to adenocarcinomas. For MCT2, the significant alterations in the expression 
along the progression to the invasive phenotype did not follow a clear increase/decrease pattern. 
Importantly, it was quite interesting to note that both MCT1 and MCT4 were only expressed in the 
parabasal and basal cell layers of the normal squamous epithelium, are lost in the upper layers, but 
‘‘reappear’’ in altered cells. It seems that these altered cells recover the MCT expression 
phenotype of the parabasal cell layer, which represents the main proliferative pool of cells. Also, 
MCT2 was more frequently observed in squamous cell carcinomas, while MCT4 was more 
frequently observed in adenocarcinomas. Importantly, HPV-positive pre-invasive cases expressed 
more MCT1 and MCT4 than HPV negative pre-invasive cases, and also presented more MCT1 in 
plasma membrane. In the second study, CD147 expression was evaluated in the same series of 
cervical lesions, aiming to evaluate the association between CD147 and MCT expression and 
support, in human samples, the role of CD147 as a chaperone of MCT1 and MCT4. CD147 was 
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increased in all cervical lesions, as compared to normal corresponding tissues, and, importantly, 
CD147 was more frequently expressed in MCT1 and MCT4 positive cases. However, it is 
important to note that these associations were not between plasma membrane expressions, 
excluding the role in protein trafficking to the plasma membrane. Moreover, co-expression of 
MCT1 and CD147 was associated with lymph-node metastasis in adenocarcinomas. 
In conclusion, these results point to an important role of both MCT1 and MCT4, as well as 
their co-expression with CD147, in cervical cancer cell metabolic and microenvironmental 
adaptations along progression to invasive carcinomas. 
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3.2. PUBLISHED RESULTS 
The results presented in this chapter were published in international scientific periodicals 
with referees: 
Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jubé LF, 
Queiroz GS, Schmitt F, Baltazar F (2008). Increasing expression of monocarboxylate transporters 
1 and 4 along progression to invasive cervical carcinoma. Int J Gynec Pathol 27:568-574;  
Pinheiro C, Longatto-Filho A, Pereira SM, Etlinger D, Moreira MA, Jubé LF, Queiroz GS, 
Schmitt F, Baltazar F (2009). Monocarboxylate transporters 1 and 4 are associated with CD147 in 
cervical carcinoma. Dis Markers 26:97-103. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results presented in this chapter were also presented as poster in the following international 
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3.2.2. MONOCARBOXYLATE TRANSPORTERS 1 AND 4 ARE ASSOCIATED WITH CD147 IN 
CERVICAL CARCINOMA
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4.1. CHAPTER OVERVIEW 
The primary epithelial tumour of the stomach is the adenocarcinoma, which develops from 
the stomach mucosa, usually maintaining glandular differentiation [1]. Clinical and 
epidemiological studies have suggested a link between gastric cancer and concurrent or previous 
infection with a bacterium or virus. In this context, Helicobacter pylori emerges as a contributor 
for gastric cancer in around 60% of cases and multiple studies have shown that H. pylori infection 
is associated with a 2.7- to 12-fold increase in risk of gastric cancer development [2]. 
It is widely known that the normal gastric environment is very acidic and many pH 
regulators are involved in cellular homeostasis, including AE, NHE and Na+/HCO3- co-transporter 
[3]. Gastric mucosa is protected from the acidic environment by different mechanisms, including 
the mucus-bicarbonate-phospholipid “barrier” [4]; however, this barrier may be impaired in 
different clinical conditions, such as H. pylori infection [5,6], contributing to perpetuation of 
chronic inflammation and gastric carcinogenesis [5]. 
Little is known on the metabolic features of gastric cancer cells, however, recent studies 
point at an enhanced glycolytic metabolism in gastric carcinoma [7,8]. 
In the following study, already published in an international periodical with referees, aiming 
to determine if MCTs may have an important role in gastric cancer, MCT1, MCT4 and CD147 
expressions were evaluated in a series of 190 gastric primary tumours, as well as in 71 non-
neoplastic tissues and 42 lymph-node metastases. In contrast to what was found in the previous 
types of tumours, neither MCT1 nor MCT4 were up-regulated in gastric adenocarcinomas. 
Actually, MCT4 expression was more frequently observed in normal gastric mucosa than in 
gastric cancer cells and even less frequently observed in lymph-node metastasis, indicating a 
progressive loss of this MCT isoform with disease progression. Also, MCT4 expression was 
associated with Lauren’s classification of intestinal-type carcinoma. MCT1 and CD147 were 
expressed similarly in normal gastric mucosa, primary tumours and lymph-node metastasis; 
however, MCT1 was present in the majority of samples (around 80%) while CD147 was present in 
less than a half of the samples. This may indicate that MCT1 has a major contribution in gastric 
homeostasis, which is maintained along carcinogenesis, while CD147 should have a more modest 
role in this type of cancer. Both MCT1 and MCT4 expressions were positively associated with 
CD147 and, importantly, the prognostic value of CD147 was associated with co-expression with 
MCT1, but not with MCT4. 
In conclusion, these results suggest that, although not up-regulated in gastric carcinoma, the 
complex MCT1/CD147 may have an important prognostic value in this type of tumour. 
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4.2. PUBLISHED RESULTS 
The results presented in this chapter were published in an international scientific periodical 
with referees: 
Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJC, Zilberstein B, 
Cecconello I, Alves VAF, Schmitt F, Baltazar F (2009). The prognostic value of 
CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric 
cancer. Eur J Cancer 45:2418-2424. 
 
 
 
 
 
 
 
 
 
The results presented in this chapter were also presented as poster in the following international 
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Third Intercontinental Congress of Pathology, 2008, Barcelona, Spain. Pinheiro C, Longatto-Filho 
A, Ferreira L, Simões K, Alves V, Schmitt F, Baltazar F. Monocarboxylate transporter expression 
correlates with CD147 in gastric cancer. Abstract published in conference proceedings (Virchows Arch 
452 (Suppl. 1):S202-S203); 
Twenty-seventh International Congress of the International-Academy-of-Pathology, 2008, Athens, 
Greece. Simoes K, Longatto A, Pinheiro C, Schmitt F, Ressio RA, Baltazar F, Alves V. Increased apoptosis 
in gastric carcinogenesis progression can be influenced by mechanisms involved in tumoral 
microenviroment pH control. Abstract published in conference proceedings (Histopathology 53 (Sp. Iss. 
1):162-163); 
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4.2.1. THE PROGNOSTIC VALUE OF CD147/EMMPRIN IS ASSOCIATED WITH 
MONOCARBOXYLATE TRANSPORTER 1 CO-EXPRESSION IN GASTRIC CANCER
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5.1. CHAPTER OVERVIEW 
As the majority of carcinogenesis processes, the progression of normal mammary epithelium 
into invasive carcinoma is widely accepted as a multistep process, where different events like loss 
of tumour-suppressor function, abnormal oncogene activation, abnormal response to growth 
factors, among others, take place [1]. 
FdG-PET is considered the most reliable imaging technique for the diagnosis and prognosis 
of breast cancer, especially regarding the detection of distant metastases, recurrent disease as well 
as monitoring response to therapy [1]. As increased glucose uptake by cancer cells is on the basis 
of this imaging technique, breast cancer cells have to exhibit enhanced glycolytic rates, which has 
been confirmed by some studies [2,3]. 
Although MCT expression has been evaluated in some breast cancer cell lines, no data on 
the frequency or prognostic value of MCT expression in human breast carcinoma was available. 
In this chapter, three distinct studies in breast carcinoma are presented. Firstly, results 
already published in an international periodical with referees showed an increase of MCT1 
expression in breast carcinoma, in a series comprising 249 samples. Also, both MCT1 and MCT4 
expressions were associated with CD147. Importantly, MCT1 and CD147, alone or in co-
expression, were associated with basal-like subtype (a more aggressive breast cancer group) and 
other poor prognostic variables, pointing at a role of MCT1/CD147 in breast carcinoma 
aggressiveness. In the second study, already submitted for publication, GLUT1 and CAIX were 
evaluated as indicators of the hypoxia-induced adaptations towards a glycolytic phenotype. 
Importantly, both MCT1 and CD147, but not MCT4, were significantly associated with GLUT1 
and CAIX. Also, additional data on the prognostic value of GLUT1 and CAIX was provided, 
showing the association of these two proteins with poor prognostic variables, and supporting the 
association of CAIX with shorter disease-free survival. Finally, in vitro studies were performed to 
shed some light into the contribution of MCT1 to breast cancer cell metabolism and viability. For 
that, MCT1 inhibition studies were performed in a variety of human breast cancer cells. In this 
work, after analysing the expression of MCT1, MCT4, CD147, as well as GLUT1 and CAIX in 
the human breast cancer cell lines MCF-7/AZ, SkBr3, MDA-MB-468, BT-20, MDA-MB-231 and 
Hs578T, MCT1 inhibition studies were carried out using the MCT1 classical inhibitor CHC. This 
inhibitor induced a significant decrease in total biomass of almost all cell lines, though at different 
magnitudes, which did not correlate with MCT1 expression. Importantly, MDA-MB-468, a basal-
like subtype breast cancer line, showed a CHC-induced inhibition of total biomass, which was 
accompanied with a decrease in glucose consumption and lactate production, evidencing the role 
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of MCT1 in this group of breast carcinomas. However, the most sensitive cell line, MDA-MB-
231, was negative for MCT1 expression and CHC-induced inhibition was not accompanied by 
extracellular decrease in lactate amounts, suggesting an off-target effect of CHC. 
Overall, the results presented in this chapter point at MCT1 as a potential therapeutic target 
in breast cancer, with special emphasis on basal-like subtype, which so far does not have a specific 
molecular therapy. 
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5.2. PUBLISHED RESULTS 
This chapter includes the following results, published in an international scientific 
periodical with referees: 
Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F. 
Monocarboxylate transporter 1 is upregulated in basal-like breast carcinoma. Histopathology In 
press. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following results were also presented as poster in the following international scientific 
meetings: 
CNIO-ONCOTRAIN Meeting: “New battlefields in human cancer- Attacking in many fronts”, 2008, 
Madrid, Spain. Pinheiro C, Sousa B, Ferreira L, Dufloth R, Vieira D, Schmitt F, Baltazar F. 
Monocarboxylate transporter 1 is upregulated in ER negative breast cancer; 
Eleventh Cancer Research UK Beatson International Cancer Conference, 2008, Glasgow, United 
Kingdom. Pinheiro C, Sousa B, Ferreira L, Dufloth R, Vieira D, Schmitt F, Baltazar F. Monocarboxylate 
transporter 1 (MCT1) overexpression is associated with poor prognosis in breast carcinomas. 
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5.2.1. MONOCARBOXYLATE TRANSPORTER 1 IS UP-REGULATED IN BASAL-LIKE 
BREAST CARCINOMA 
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5.3. SUBMITTED RESULTS 
This chapter also comprises the following manuscript, submitted for publication to an 
international scientific periodical with referees: 
Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F. 
GLUT1 and CAIX expression profiles in breast cancer correlate with MCT1 overexpression and 
adverse prognostic factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following results were also presented as poster in the following international scientific 
meeting: 
EACR-21, 2010, Oslo, Sweden. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, 
Schmitt F, Baltazar F. GLUT1 and CAIX expression profiles in breast cancer correlate with MCT1 
overexpression.
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5.3.1. GLUT1 AND CAIX EXPRESSION PROFILES IN BREAST CANCER CORRELATE 
WITH MCT1 OVEREXPRESSION AND ADVERSE PROGNOSTIC FACTORS
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GLUT1 and CAIX expression profiles in breast cancer correlate with 
MCT1 overexpression and adverse prognostic factors 
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ABSTRACT 
The goal of the present work was to evaluate the correlation of glucose transporter 1 (GLUT1) and carbonic 
anhydrase IX (CAIX) with the monocarboxylate transporters 1 (MCT1) and 4 (MCT4) and their chaperone, CD147, in 
breast cancer. The clinico-pathological value of GLUT1 and CAIX was also evaluated. For that, we analysed the 
immunohistochemical expression of GLUT1 and CAIX, in a large series of invasive breast carcinoma samples 
(n=124), previously characterised for MCT1, MCT4 and CD147 expression. GLUT1 expression was found in 46% of 
the cases (57/124), while CAIX expression was found in 18% of the cases (22/122). Importantly, both MCT1 and 
CD147, but not MCT4, were associated with GLUT1 and CAIX expression. Also, GLUT1 and CAIX correlated with 
each other. Concerning the clinico-pathological values, GLUT1 was associated with high grade tumours, basal-like 
subtype, absence of progesterone receptor and presence of vimentin and Ki67 expression. Additionally, CAIX was 
associated with high tumour size, high histological grade, basal-like subtype, absence of estrogen and progesterone 
receptors and presence of basal cytokeratins and vimentin expression. Finally, patients with CAIX positive tumours 
had a significant shorter disease-free survival.  
The association between MCT1 and both GLUT1 and CAIX may result from the hypoxia-mediated 
metabolic adaptations, which will confer a glycolytic, acid-resistant and more aggressive phenotype to cancer cells. 
 
Keywords: GLUT1; CAIX; monocarboxylate transporters (MCT); CD147/EMMPRIN; breast carcinoma; 
immunohistochemistry. 
Abbreviations: CA (carbonic anhydrase); ER (estrogen receptor); GLUT (glucose transporter); HIF-1α (hypoxia 
inducible-factor 1 alpha); MCT (monocarboxylate transporter); PR (progesterone receptor). 
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INTRODUCTION 
Early epithelial carcinogenesis occurs under 
hypoxic conditions, since altered cells are separated 
from the vascularised stroma, source of oxygen and 
nutrients. To maintain the needed ATP levels, cancer 
cells increase their rates of glycolysis, acquiring a 
significant proliferative advantage. However, this 
phenotype leads to an overload of lactic acid, which 
must be exported from the cell, causing a decrease in the 
extracellular pH.  
Constitutive up-regulation of glycolysis requires 
additional adaptations, namely, resistance to apoptosis 
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and up-regulation of membrane transporters to maintain 
normal intracellular pH 1. The need to increase glucose 
uptake, to allow high glucose consumption rates, is 
achieved by up-regulation of glucose transporters 
(GLUT) in the plasma membrane of cancer cells, 
especially the hypoxia-responsive GLUT1 2;3. The role 
of GLUT1 in breast cancer remains poorly elucidated 4;5. 
Besides being an adaptation to high glycolytic 
phenotype, acidic environment represents per se a 
significant advantage for tumour cells since it is 
associated with increased migration, invasion and 
metastases, among others 1;6;7. Although lactate 
produced by glycolysis under hypoxic conditions is a 
significant contributor to the acidic extracellular pH, 
there is also a substantial contribution from carbonic 
acid 8. In this context, the hypoxia-responsive carbonic 
anhydrase isoforms, CAIX and CAXII, emerge as 
important contributors to the regulation of cancer cell 
intracellular pH 9-11, with CAIX, in particular, being 
associated with poor prognosis in breast cancer 12-15.  
Another important group of proteins involved in 
intracellular pH regulation are monocarboxylate 
transporters (MCTs), which are also responsible for 
transmembrane transport of lactate 16. By performing 
these two inter-dependent activities (lactate transport 
coupled with a proton), MCTs appear as strong potential 
targets for cancer therapy. Indeed, there are evidences 
for the up-regulation of MCTs in tumours, such as high 
grade glial neoplasms 17;18, colorectal 19;20, lung 21, 
cervical 22, and breast carcinomas 23. Besides analysing 
MCT expression in tumours, our group also assessed for 
the first time the clinico-pathological value of their 
overexpression 20;22-24. MCT expression appears to be 
influenced by altered physiologic conditions; however, 
the underlying molecular events involved in MCT 
regulation are poorly understood. Recently, it was 
demonstrated that proper expression and activity of 
MCT1 and MCT4 requires co-expression of CD147, 
also known as EMMPRIN or Basigin 25-27. Based on 
this, we described the association between CD147 and 
both MCT1 and MCT4 in human cervical 28, gastric 24 
and breast cancer 23. Furthermore, the hypoxia 
inducible-factor 1 alpha (HIF-1α), which regulates many 
genes codifying proteins involved in the glycolytic 
pathway (like GLUT1) and pH regulation (like the 
Na+/H+ exchanger NHE1 and both CAIX and CAXII) 29, 
also regulates MCT1 30 and MCT4 30;31. However, there 
is some controversy around MCT1 regulation by 
hypoxia, with some studies reporting MCT1 repression 
by hypoxia 31;32. 
One of the goals of the present study was to 
evaluate the association between the HIF-1α 
downstream targets GLUT1 and CAIX and both MCT1 
and MCT4, as well as their chaperone, CD147, in 
invasive breast carcinomas. We also intended to 
strengthen the clinico-pathological value of GLUT1 and 
CAIX in breast cancer. 
 
 
MATERIALS AND METHODS 
Case selection 
Case selection was based on availability of follow 
up information and amount of material, ensuring 
adequate numbers for statistical analysis. Thus, a series 
of 124 formalin-fixed paraffin embedded breast 
carcinoma tissues was retrieved from the files of the 
Department of Pathology, Hospital do Divino Espírito 
Santo, Azores, Portugal, and from the Federal 
University of Santa Catarina, Florianopolis-SC, Brazil. 
Haematoxylin/eosin stained sections of all cases were 
reviewed by three pathologists (R.D., D.V. and F.S.). 
Tumour samples were organised into 14 tissue 
microarrays (TMAs), with 20 tumour cores (2 mm 
diameter) each, also including several samples of 
normal breast tissue. Each case was represented in the 
TMA by at least two cores. Relevant clinico-
pathological data included tumour size (TNM), 
molecular subtype, histological grade, estrogen receptor 
(ER) and progesterone receptor (PR), human epidermal 
growth factor receptor 2 (HER2), epidermal growth 
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factor receptor 1 (EGFR), basal cytokeratins (CK5 and 
CK14), vimentin and Ki67 expression status. 
Information on lymph-node metastasis, disease-free 
survival and overall survival was also available. These 
tumour samples were previously analysed by our group 
for MCT1, MCT4 and CD147 expressions 23. 
 
Immunohistochemistry 
GLUT1 and CAIX detection 
Immunohistochemistry was performed based on 
the streptavidin–biotin–peroxidase complex principle 
(Ultravision Detection System Anti-polyvalent, HRP, 
Lab Vision Corporation, Fremont, CA), using rabbit 
polyclonal primary antibodies raised against GLUT1 
(ab15309, AbCam, Cambridge, UK, diluted 1:500) and 
CAIX (ab15086, AbCam, Cambridge, UK, diluted 
1:2000). Briefly, deparaffinised and rehydrated sections 
were immersed in citrate buffer (0.01M, pH 6.0) heated 
up to 98ºC, in a water bath, for 10 minutes (GLUT1) or 
20 minutes (CAIX) and washed in PBS. Endogenous 
peroxidase activity was blocked with 3% hydrogen 
peroxide in methanol for 10 minutes, followed by 
washing with PBS. Tissue sections were incubated with 
blocking solution for 10 minutes and incubated at room 
temperature with the primary antibody for 2 hours. 
Sections were then sequentially washed in PBS and 
incubated with biotinylated goat anti-polyvalent 
antibody for 10 minutes, streptavidin peroxidase for 10 
minutes, and developed with 3,3’-diamino-benzidine 
(DAB+ Substrate System, Dako, Carpinteria, CA) for 10 
minutes. Negative controls were performed by using an 
adequate serum controls for the primary antibodies 
(N1699, Dako, Carpinteria, CA) and skin and gastric 
mucosa were used as positive controls for GLUT1 and 
CAIX, respectively. Tissue sections were counterstained 
with haematoxylin and permanently mounted. 
 
Immunohistochemical evaluation 
As described for MCT and CD147 23, GLUT1 and 
CAIX immunohistochemical reactions were scored 
semi-quantitatively for plasma membrane staining as 
follows: 0: 0% of immunoreactive cells; 1: <5% of 
immunoreactive cells; 2: 5-50% of immunoreactive 
cells; and 3: >50% of immunoreactive cells. Also, 
intensity of staining was scored semi-qualitatively as 
follows: 0: negative; 1: weak; 2: intermediate; and 3: 
strong. The final score was defined as the sum of both 
parameters (extension and intensity), and grouped as 
negative (score 0 and 2) and positive (score 3-6), as 
previously described.  
 
Statistical analysis 
Data were stored and analysed using the Statview 
statistical software (SAS Institute Inc., Cary, NC). All 
comparisons were examined for statistical significance 
using Pearson’s chi-square (χ2) test or Fisher’s exact 
test, as adequate, being the threshold for significance p 
values <0.05. Disease-free and overall survival curves 
were plotted using the method of Kaplan-Meier and data 
compared using the log-rank test. A cut-off of 60 
months (5 years) was considered, since in the first 5 
years following primary therapy recurrence rates are 
expected to be highest, especially in series with high 
number of ER negative cases like ours, where the hazard 
of recurrence is higher 33. Cases lacking one or more of 
the clinico-pathological variables were not included in 
the specific statistical analysis. 
 
 
RESULTS 
A total of 124 breast carcinoma samples, organised 
into TMAs (Tissue Microarrays), were assessed for 
GLUT1 and CAIX immunohistochemical expressions.  
In general, positive GLUT1 expression was 
observed in both plasma membrane and cytoplasm 
(Figure 1A), while CAIX expression was mainly 
observed in the plasma membrane, with some cases 
presenting also cytoplasm staining (Figure 1B). GLUT1 
expression was observed only in the epithelium cells of 
1 out 20 normal samples evaluated (5%), with a
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Figure 1. Immunohistochemical expression of glucose transporter 1 (GLUT1), carbonic anhydrase IX (CAIX) and monocarboxylate transporter 1 
(MCT1), in breast carcinoma samples. GLUT1 and CAIX expression was frequently observed in perinecrotic regions (A and B, respectively). 
CAIX expression was usually focal and mainly restricted to tumour cells. Lower panel shows a breast cancer case simultaneously positive for 
MCT1 (C), GLUT1 (D) and CAIX (E), with staining in the same tumour region. 
 
significantly higher frequency (46%) in tumour samples 
(57/124, p=0.0005), while CAIX expression was absent 
in normal tissue but was found in 18% (22/122) of 
breast cancer cases (p=0.0388). Importantly, the 
expression of both molecules was frequently observed in 
peri-necrotic regions, as can be observed in Figure 1 (A 
and B), especially CAIX which was usually focal and 
mainly restricted to tumour cells, adjacent to areas of 
necrosis. 
Importantly, when comparing the expression of the 
previously analysed MCT1, MCT4 and CD147 23 with 
GLUT1 and CAIX, we found that both MCT1 and 
CD147, but not MCT4, were more frequently expressed 
in GLUT1 and CAIX positive tumour samples (Table 
1). Also, as expected, GLUT1 and CAIX were 
significantly co-expressed, with 81.8% (18/22) of CAIX 
positive cases also positive for GLUT1 versus 37.5% 
(36/96) GLUT1 positive in the CAIX negative group, 
p=0.0002. Figure 1 (C, D, E) shows a breast cancer case 
simultaneously positive for MCT1, GLUT1 and CAIX, 
in the same tumour area.  
Assessment of the clinico-pathological value of 
GLUT1 and CAIX also retrieved important results 
(Table 2). We found significant associations between 
 
Table 1. Association of CAIX and GLUT1 with MCT1, MCT4 and CD147 expression in breast 
carcinoma samples. 
 n MCT1 Positive (%) p 
MCT4 
Positive (%) p 
CD147 
Positive (%) p 
GLUT1 106  <0.0001  0.3473  0.0032 
Negative 55 1 (1.8)  4 (7.3)  2 (3.6)  
Positive 51 15 (29.4)  7  (13.7)  12 (23.5)  
CAIX 105  <0.0001  0.6897  0.0005 
Negative 84 6 (7.1)  8 (9.5)  7 (8.3)  
Positive 21 10 (47.6)  3 (14.3)  8 (38.0)  
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GLUT1 expression and high grade tumours (p=0.0014), 
basal-like subtype (p=0.0008), absence of progesterone 
receptor (p=0.0162), presence of vimentin (p=0.0033) 
and high Ki67 expression (p=0.0339). Additionally, 
CAIX was associated with the majority of the clinico-
pathological parameters analysed, including tumour size 
(p=0.0034), histological grade (p=0.0263), molecular 
subtype (p=0.0050), ER and PR negativity (p=0.0014 
and p=0.0292, respectively), expression of CK5 
(p=0.0002), CK14 (p=0.0102) and vimentin (p=0.0004). 
Analysis of GLUT1 expression and patient’s survival 
(disease-free survival and overall survival) showed no 
significant differences between negative and positive 
groups (data not shown), but, importantly, patients with 
CAIX positive tumours had a lower disease free-
survival than patients with CAIX negative tumours 
(43.2 versus 52.4 months, respectively, p=0.045) (Figure 
2). No significant differences in overall survival were 
observed between the CAIX negative group and the 
CAIX positive group. 
 
Table 2. Associations of CAIX and GLUT1 expression with clinico-
pathological data from breast cancer cases. 
Clinico-pathological data 
GLUT1 CAIX 
n Positive (%) p n 
Positive 
(%) p 
T size (TNM) 121  0.5218 119  0.0034 
T1 46 23 (50.0)  45 6 (13.3)  
T2 63 25 (39.7)  63 9 (14.3)  
T3 12 6 (50.0)  11 6 (54.5)  
Histological grade 124  0.0014 122  0.0263 
I 23 5 (21.7)  24 2 (8.3)  
II 55 22 (40.0)  51 6 (11.8)  
III 46 30 (65.2)  47 14 (29.8)  
Subtype 114  0.0008  113  0.0050 
Luminal 78 31 (39.7)  79 8 (10.1)  
Basal-like 25 20 (80.0)  24 9 (37.5)  
HER2 overexpressing 11 3 (27.3)  10 3 (30.0)  
Estrogen receptor 124  0.1059 122  0.0014 
Negative 45 25 (55.6)  42 14 (33.3)  
Positive 79 32 (40.5)  80 8 (10.0)  
Progesteron e receptor 124  0.0162 122  0.0292 
Negative 75 41 (54.7)  73 18 (24.6)  
Positive 49 16 (32.6)  49 4 (8.2)  
HER2 overexpression 123  0.5885 121  0.4556 
Negative 110 51 (46.4)  109 19 (17.4)  
Positive 13 5 (38.5)  12 3 (25.0)  
EGFR 124  >0.9999 122  0.6643 
Negative 115 53 (46.1) 113 20 (17.7)  
Positive 9 4 (44.4)  9 2 (22.2)  
CK5 124  0.1188 122  0.0002 
Negative 98 42 (42.8)  97 11 (11.3)  
Positive 26 15 (57.7)  25 11 (44.0)   
CK14 121  0.0508 121  0.0102 
Negative 114 51 (44.7)  115 18 (15.6)  
Positive 7 6 (85.7)  6 4 (66.7)  
Vimentin 106  0.0033 106  0.0004 
Negative 89 38 (42.7)  88 12 (13.6)  
Positive 17 14 (82.4)  18 9 (50.0)  
Ki67 124  0.0339 122  0.5214 
< 20% 65 24 (36.9)  63 10 (15.9)  
> 20% 59 33 (55.9)  59 12 (20.3)  
Lymph-node metastasis 117  0.6326 115  0.5840 
Absent 58 24 (41.4)  55 8 (14.5)  
P resent 59 27 (45.8)  60 11 (18.3)  
  
 
 
Role of monocarboxylate transporters in solid tumours Pinheiro C 
 
138  
 
 
Figure 2. Disease-free survival (DFS) curve regarding CAIX immunoreaction in breast cancer patients. Patients 
with positive tumours for CAIX expression show shorter disease-free survival (interrupted line) than patients with 
CAIX negative tumours (continuous line) (p = 0.045). 
 
DISCUSSION 
Up-regulation of glucose conversion into lactate, 
even in the presence of oxygen (Warburg effect), has 
been described as a possible adaptive mechanism to 
overcome intermittent hypoxia in pre-malignant lesions. 
This metabolic switch leads to an increase in acid 
production by cancer cells and, therefore, the need for 
further adaptation by means of intracellular pH 
regulation and resistance to extracellular acidity 1. In 
this perspective, MCTs emerge as important 
contributors to cancer cell adaptation due to their 
function, on one hand, of lactate export, allowing 
continuous glycolysis, and, on the other hand, of tumour 
intracellular pH regulation and induction of extracellular 
acidosis, by co-transporting lactate and a proton. 
Although some literature review the contribution of 
MCTs to the glycolytic and acidic phenotype of tumours 
34;35, the significance of tumour MCT expression in this 
context is still not clear 19;21. Thus, the main aim of the 
present work was to determine if glycolytic and acid-
resistant tumours, with up-regulation of GLUT1 and 
CAIX, present a higher expression of MCTs, supporting 
the involvement of these transporters in the metabolic 
adaptations of cancer cells. 
GLUT1, involved in glucose uptake, is up-
regulated in a variety of tumours (for review see 36), 
being the hypoxia transcription factor HIF-1α the major 
regulator of its expression in cancer cells 37;38. HIF-1α, 
the master transcriptional regulator of tumour cell 
adaptation to hypoxic stress, activates a number of 
genes, many of which code for protein involved in O2 
delivery, angiogenesis, energy preservation (including 
glucose transporters and glycolytic enzymes), and other 
processes essential to tumour cell survival, proliferation, 
and spread 29. Moreover, GLUT1, CAIX and MCT4 are 
downstream targets of HIF-1α 30;31;39 and both GLUT1 
and CAIX are also recognised as tumour hypoxia 
markers 40.  However, in our study, MCT4 expression 
was not increased in GLUT1 or CAIX positive tumours. 
In contrast, MCT1 was more frequently expressed in 
both GLUT1 and CAIX positive tumours, pointing to a 
hypoxia dependent up-regulation of this MCT isoform, 
which is accompanied by co-expression of its chaperone 
CD147, essential for plasma membrane localisation and 
transporter activity 25-27;41;42. This finding is of major 
importance since it reinforces the induction of MCT1 
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expression by hypoxia 30, which is contested by some 
groups 31;32. With these associations, one can support the 
role of functional MCT1 as the lactate transporter 
responsible for lactate efflux in highly glycolytic breast 
cancer cells, especially in basal-like tumours. The 
transport activity of MCT1 is considered one of the most 
important mechanisms of intracellular pH regulation 16. 
Besides MCTs, carbonic anhydrases, especially CAIX, 
play a major role in maintenance of intracellular (and 
extracellular) pH levels, by contributing to the extrusion 
of the protons generated by the high metabolic rates of 
glycolytic cancer cells. At the tumour cell surface, 
CAIX catalyses the extracellular trapping of acid by 
hydrating the cell-generated CO2 into HCO3- and H+ 11. 
Thus, it is not surprising to see an association between 
MCT1 and both GLUT1 and CAIX, which is likely a 
result of the overall HIF-1α-mediated metabolic 
adaptations, conferring a glycolytic, acid-resistant 
phenotype to cancer cells.  
According to the previously described 14;43;44, in 
our tumour series, GLUT1 and CAIX were mainly 
observed in the vicinity of necrotic areas (a consequence 
of tumour hypoxia), which supports the hypoxia-
mediated regulation of the expression of these proteins. 
Both hypoxia markers were absent in the normal breast 
tissue, but up-regulated in breast tumour tissues, with 
expression frequencies concordant with previous reports 
4;5;12;13;15;45. Although the clinico-pathological value of 
GLUT1 and CAIX in breast cancer has already been 
studied by others 5;12-15, our data strengthens the 
importance of these proteins as prognostic markers, 
especially GLUT1, which has been few explored in 
breast cancer 4;5. So far, GLUT1 has been associated 
with lower disease-free survival, loss of ER and PR 4 
and both higher grade 4;5 and proliferative activity 
(through Ki67 expression) 5. In the present work, 
although we did not find associations of GLUT1 with 
disease-free or overall survival, GLUT1 was more 
frequently expressed in high grade tumours, negative for 
PR and with high proliferative index (Ki67). 
Importantly, we found GLUT1 to be more frequently 
expressed in basal-like tumours, as well as in vimentin 
positive tumours. In respect to CAIX, more data has 
been published in breast carcinomas, which identifies 
CAIX as a good marker of aggressive tumour behaviour. 
This protein was positively correlated with higher 
tumour size, basal-like 15 and high grade tumours, loss 
of ER 12;14;15;46 and PR 46 as well as with shorter disease-
free survival 13-15.  Here, we support all the previous 
findings described by other groups, by associating 
CAIX expression with high histological grade, loss of 
ER and PR and, importantly, basal-like subtype and 
disease-free survival. These results suggest that the 
basal-like subtype tumours may be more representative 
of the glycolytic, acid-resistant phenotype proposed for 
cancer cells and this hypoxia mediated phenotype may 
explain, at least partly, the more aggressive phenotype 
of this breast carcinoma subtype. 
In the present study, we investigated the expression 
of the key hypoxia regulated proteins GLUT1 and 
CAIX. Importantly, they were positively associated with 
the major lactate transporter, MCT1, especially in a 
subset of aggressive breast carcinomas (basal-like), 
where these proteins are more frequently expressed. 
Since this subtype of tumours does not have a specific 
molecular therapy 47, the development of therapeutic 
approaches targeting these particular metabolic features 
could be a promising strategy to be explored in the 
treatment of basal-like breast tumours.  
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5.4. UNPUBLISHED RESULTS 
Finally, this chapter also comprises the following unpublished results, entitled “Sensitivity 
of breast cancers to CHC, a monocarboxyate transporter 1 inhibitor”, to be submitted for 
publication in an international scientific periodical with referees. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following results were also presented as poster in the following national scientific meeting: 
XIX Porto Cancer Meeting, 2010, Porto, Portugal. Pinheiro C, Pinheiro S, Gonçalves V, Vieira A, 
Paredes J, Schmitt F, Baltazar F. Sensitivity of breast cancer cells to CHC, an inhibitor of 
monocarboxylate transporter 1. 
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5.4.1. SENSITIVITY OF BREAST CANCER CELLS TO CHC, A MONOCARBOXYLATE 
TRANSPORTER 1 INHIBITOR
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Sensitivity of breast cancer cells to CHC, a monocarboxylate transporter 1 
inhibitor 
 
Céline Pinheiro, B.Sc.1, Sílvia Pinheiro, B.Sc.1, Vera Gonçalves, B.Sc.1, André Vieira, B.Sc.2, 
Joana Paredes, Ph.D.2, Fernando Schmitt, M.D., Ph.D., F.I.A.C.2,3, Fátima Baltazar, Ph.D.1* 
 
1Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of 
Gualtar, 4710-057 Braga, Portugal; 
2IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; 
3Federal University of Santa Catarina – UFSC – Florianópolis (SC), Brazil; 4Medical Faculty of the University of 
Porto, Porto, Portugal. 
 
ABSTRACT 
Tumour microenvironment is known to be acidic due to the high glycolytic rates of tumour cells. 
Monocarboxylate transporters (MCTs) are one of the major players responsible for the maintenance of tumour 
intracellular pH, which is achieved by the transport of lactate coupled with a proton, through the cell plasma 
membrane. It is widely known that acidification of the extracellular microenvironment has important implications in 
tumour progression and, therefore, MCTs have been suggested as potential targets for cancer therapy. We have 
recently described the up-regulation of monocarboxylate transporter 1 (MCT1) in breast carcinomas and its 
association with poor prognostic variables, such as basal-like subtype and high grade tumours. Therefore, we aimed to 
evaluate the effect of MCT1 inhibition in different breast cancer cell lines. 
The human breast cancer cell lines MCF-7/AZ, SkBr3, MDA-MB-468, BT-20, MDA-MB-231 and Hs578T were 
used for this study. MCT1, MCT4 and CD147 expressions, as well as CAIX and GLUT1, were evaluated by 
immunocytochemistry in paraffin cell blocks. Also, the effect of the MCT1 inhibition in cancer cell viability and 
metabolic profile was evaluated using the MCT1 classical inhibitor α-cyano-4-hydroxycinnamate (CHC). 
MCT1, MCT4 and CD147 were differently expressed among the breast cancer cell lines, being MCF-7/AZ, 
SkBr3 and MDA-MB-231 negative and MDA-MB-468, BT-20 and Hs578T positive for MCT1 plasma membrane 
expression. In MDA-MB-468, the CHC-induced inhibition (IC50 value of 9.3 mM) was accompanied by a decrease in 
both glucose consumption and lactate production. Although negative for MCT1 expression, MDA-MB-231 showed 
the lowest IC50 value after inhibition with CHC (5.3 mM); however, this inhibition in cell proliferation/viability was 
not accompanied by a decrease in glucose consumption and lactate production. BT20 showed the highest IC50 value 
(23.5 mM), with no effect on glucose or lactate extracellular concentrations. 
In this study, we evaluated, for the first time, the sensitivity of different breast cancer cell lines to the classical 
MCT1 inhibitor CHC. The results obtained here led us to hypothesise that MCT1 inhibition may be a good therapeutic 
strategy to treat breast cancer, with special emphasis on basal-like subtype, which so far does not have a specific 
molecular therapy. 
 
Keywords: Monocarboxylate transporter, breast carcinoma, lactate, CHC, metabolism. 
Abbreviations: AE (anion exchanger); CA (carbonic anhydrase); CHC (α-cyano-4-hydroxycinnamate); DMSO 
(dimethyl sulfoxide); FBS (fetal bovine serum); FdG-PET (18F-fluorodeoxyglucose positron emission tomography); 
GLUT (glucose transporter); HIF-1α (hypoxia inducible-factor 1 alpha); MCT (monocarboxylate transporter); siRNA 
(small-interfering RNA). 
 
*Corresponding author: Fátima Baltazar, Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 
Campus of Gualtar, 4710-057 Braga, Portugal, Phone: +351 253604828, Fax: +351 253604820, E-mail: fbaltazar@ecsaude.uminho.pt 
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INTRODUCTION 
The increased uptake of glucose by cancer cells 
is a widely described phenomenon, being the rationale 
behind the whole-body noninvasive 18F-
fluorodeoxyglucose positron emission tomography 
(FdG-PET). This imaging technique is considered to 
be the most reliable for the diagnosis and prognosis of 
breast cancer, especially regarding the detection of 
distant metastases, recurrent disease as well as 
monitoring therapy response [1]. This increased 
uptake of glucose, especially through glucose 
transporter 1 (GLUT1), is a consequence of an 
increased glycolytic metabolism that generates acids 
inside the cell, inducing the up-regulation of some pH 
regulators, like carbonic anhydrases IX (CAIX) [2], to 
maintain physiological pH inside the cell, causing 
extracellular acidosis. The increased glycolytic 
metabolism ultimately leads to an increase in lactate 
release by cancer cells, contributing also to 
microenvironmental acidosis, as well as increased 
invasion capacity [3] and suppression of anticancer 
immune response [4]. More recently, a metabolic 
symbiosis between glycolytic and oxidative cancer 
cells was described, in which the peripheral and 
oxygenated oxidative cells consume the lactate 
produced by the central and less oxygenated glycolytic 
cells [5]. In this context, lactate has a central role and 
lactate transporters are currently seen as potential 
therapeutic targets in cancer treatment, with promising 
results using in vitro and in vivo models [5-11]. 
Presently, monocarboxylate transporters (MCTs) are a 
family of 14 members, with isoforms 1 to 4 being 
lactate proton symporters that exhibit different 
affinities for lactate [12]. MCT1 isoform has been 
described as the gatekeeper of cancer metabolic 
symbiosis, by up-taking lactate in the oxidative cancer 
cells [5]. Therefore, MCT1 would probably be the 
most promising isoform in this context and reports on 
MCT1 upregulation in a variety of tumours are 
becoming more frequent [8,10,13-17]. We also 
described the association of MCTs, especially MCT1, 
with poor prognostic variables [15,17,18], reinforcing 
the potential of MCT1 as cancer therapeutic target. 
Recently, our group described an increase of MCT1 
expression in breast carcinoma, when comparing with 
normal tissue. Importantly, this enhanced MCT1 
expression, as well as the expression of CD147 
(MCT1 chaperone), were associated with basal-like 
subtype tumours and other poor prognostic parameters 
[17]. 
Over the last years, different approaches have 
been used to inhibit lactate efflux from cancer cells, 
including MCT small-molecule inhibitors like α-
cyano-4-hydroxycinnamic acid (CHC) [5,6,9] and 
MCT small-interfering RNA (siRNA) [5,8,10]. 
Continued inhibition of lactate efflux inhibits pyruvate 
reduction to lactate and, therefore, prevents NAD+ 
recycling, causing metabolic crisis in tumour cells. 
MCT inhibition studies are providing evidence for the 
effectiveness of targeting the end stage of glycolysis, 
with data showing a reduction of tumour malignancy, 
enhancement of radio-sensitivity and induction of cell-
death in MCT targeted tumour tissue (for review, see 
[11]). 
Despite the promising results obtained by MCT 
inhibition, we are still far from definitely pointing at 
MCTs as effective targets for cancer therapy. Without 
doubt, more efforts are needed to increase evidence 
supporting that inhibition of metabolism, more 
specifically lactate transport and pH regulation, may 
be an alternative therapeutic strategy to use in cancer 
treatment, in a near future. Therefore, the present work 
is an attempt to provide new data supporting in the 
exploitation of MCTs as targets in breast cancer 
therapy. 
 
 
MATERIALS AND METHODS 
Cell lines  
Human breast cancer cell lines MCF-7/AZ, 
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SkBr3, MDA-MB-468, BT-20, MDA-MB-231 and 
Hs578T were obtained from ATCC or from 
collections developed in the laboratories of Drs Elena 
Moisseva (Cancer Biomarkers and Prevention Group, 
Departments of Biochemistry and Cancer Studies, 
University of Leicester, UK), Marc Mareel 
(Laboratory of Experimental Cancerology, Ghent 
University Hospital, Belgium) and Eric Lam (Imperial 
College School of Medicine, Hammersmith Hospital, 
London, UK). 
Cell culture 
All cell lines were grown in commercially 
available culture medium (DMEM, Invitrogen), 
supplemented with 10% heat-inactivated Fetal Bovine 
Serum (FBS, Invitrogen) and 1% antibiotic solution 
(penicillin–streptomycin, Invitrogen). All cell lines 
were routinely cultured at 37ºC, in a humidified 
atmosphere with 5% CO2.  
 
Protein expression assessment 
Paraffin cytoblock 
Concentrated cell suspensions were made by 
centrifuging fresh cell suspensions at 1200 rpm for 5 
minutes. After discarding the supernatant, cell pellets 
were incubated with formaldehyde 3.7% overnight 
and re-centrifuged. Cell pellets were then processed in 
an automatic tissue processor (TP1020, Leica), before 
inclusion into paraffin (block-forming unit, EG1140H, 
Leica). 
Immunocytochemistry 
Immunocytochemistry was performed for MCT1, 
MCT4, CD147 (MCT1 and MCT4 chaperone [19-
21]), GLUT1 and CAIX as previously described 
[15,22]. Briefly, deparaffinised and rehydrated 4 μm 
cytoblock sections were submitted to the adequate 
antigen retrieval, followed by inactivation of 
endogenous peroxidase activity. Slides were then 
incubated with the primary antibody and 
immunoreactivity was visualised with 3,3’-diamino-
benzidine (DAB+ Substrate System, Dako). Please see 
Table 1 for detailed aspects of each antibody used. 
Negative controls were performed by using adequate 
serum control for the primary antibodies (N1699, 
Dako). Cytoblock sections were counterstained with 
haematoxylin and permanently mounted. Cells were 
evaluated for positive expression, distinguishing 
cytoplasmic from membrane expression. 
 
 
Table 1. Detailed aspects of the immunocytochemical procedure used to visualise the different proteins. 
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Figure 1. Immunocytochemical expression of different proteins in human breast carcinoma cell lines (400x 
magnification). MCT1 was mainly found in the plasma membrane of MDA-MB-468, BT20 and Hs578T cells, while 
MCT4 was only found in the cytoplasm of all cell lines. CD147, GLUT1 and CAIX were observed at the plasma 
membrane of some tumour cell lines, at varying levels. 
 
Evaluation of the metabolism/Metabolic behaviour 
of human breast cancer cell lines 
Glucose and lactate quantification 
The metabolic behaviour of the different cell 
lines was determined by analysing basic metabolic 
parameters, i. e., extracellular concentrations of 
glucose and lactate. For metabolic studies, to minimise 
variations due to cell growth and size, as well as 
obtain measurable variations of glucose and lactate in 
a short period of time, assays were performed with 
confluent cells, in 24-well plates. After reaching 
confluence, spent medium was replaced with fresh 
complete culture medium (supplemented with FBS 
and antibiotics) and aliquots were retrieved, after 24 
and 48 hours. Glucose and lactate were quantified 
using commercial kits (Roche and SpinReact, 
respectively), according to the manufacturer’s protocol 
but scaled down to microplate volumes. Results are 
expressed as total μg/500 µl medium. 
MCT1 in vitro inhibition using the classical 
inhibitor CHC 
IC50 estimation 
To determine the CHC IC50 value for the 
different breast cancer cell lines, cells were plated in 
96-well plates, at a density ranging from 10000 to 
20000 cells per well, depending on cell growth rates. 
Cells were allowed to grow overnight prior to 
incubation with culture medium (without serum) 
containing 3-15 mM of CHC (Sigma-Aldrich, stocks 
at 0.3-1.5 M in dimethyl sulfoxide (DMSO)). Controls 
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were performed by adding DMSO to cell culture 
medium at the same dilution (1:100). The effect of 
CHC on cell number (total biomass) was evaluated by 
the Sulforhodamine B assay (SRB, TOX-6, Sigma-
Aldrich), following the manufacturer’s 
recommendations. IC50 values were estimated from 
three independent experiments, each one in triplicate, 
using the GraphPad Prism 5 software, applying a 
sigmoidal dose-response (variable slope) nonlinear 
regression, after logarithmic transformation.  
Glucose and lactate quantification 
For metabolic studies, as previously described, assays 
were performed with confluent cells, in 24-well plates. 
After reaching confluence, cells were incubated with 
2.5, 5 and/or 10 mM of CHC, as indicated in the 
results section. Cell culture medium (30 μl) was 
retrieved at 4, 8 and 12 hours, assuring confluences 
similar to the ones observed in the control. Glucose 
and lactate were quantified as mentioned above. Data 
from two independent experiments, each one in 
triplicate, was stored in GraphPad Prism 5 software. 
All conditions were examined for statistical 
significance using two-tailed Student’s t-test for mean 
comparison, being threshold for significance p values 
<0.05. 
 
 
RESULTS 
 
Protein expression 
Human breast cancer cell lines MCF-7/AZ, SkBr3, 
MDA-MB-468, BT-20, MDA-MB-231 and Hs578T 
were evaluated for MCT1, MCT4, CD147, GLUT1 
and CAIX immunocytochemical expression, as 
depicted in Figure 1. Membrane expression of MCT1 
was only observed in MDA-MB-468, BT20 and 
Hs578T cell lines, while MCT4, although differently 
expressed in the cytoplasm of all cell lines analysed, 
was not found in the plasma membrane of any of the 
cell lines. CD147 was observed in the plasma 
membrane of the 6 cell lines studied; however, MCF-
7/AZ, MDA-MB-468 and Hs578T expressed this 
protein at very low levels. GLUT1 was expressed at 
the plasma membrane, at different levels in all cell 
lines, and CAIX was only detected in a low percentage 
of cells in MDA-MB-468 and Hs578T and, at even 
lower levels in MCF-7/AZ. 
 
Metabolic behaviour of human breast cancer cell 
lines 
Glucose and lactate quantification in the culture 
medium showed different metabolic behaviours 
among the breast cancer cell lines studied (Figure 2A 
and 2B). 
 
 
Figure 2. Extracellular amounts of glucose (A) and 
lactate (B) in the different human breast carcinoma 
cell lines, along time. Results are expressed as 
mean±SEM. 
 
In general, cells consuming more glucose along 
time also produced more lactate. SkBr3 and MDA-
MB-468 showed the highest glucose consumption 
rates, followed by Hs578T and MCF-7/AZ, while 
BT20 and MDA-MB-231 presented the lowest 
consumption of glucose. On the other hand, SkBr3, 
Hs578T and MDA-MB-468 produced more lactate 
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Figure 3. CHC-induced phenotypic alterations in the human breast carcinoma cell lines MCF-7/AZ (A- control, B- 
CHC treated), SkBr3 (C- control, D- CHC treated), MDA-MB-468 (E- control, F- CHC treated), BT20 (G- control, H- 
CHC treated), MDA-MB-231 (I- control, J- CHC treated) and Hs578T (K- control, L- CHC treated). 
 
than MCF-7/AZ, MDA-MB-231 and BT20, by this 
order. 
 
MCT1 inhibition using CHC 
Human breast cancer cell lines were treated once 
with CHC at increasing concentrations (3-15 mM) 
and, 24 hours later, total cell biomass was determined 
with SRB assay (estimation of IC50 values). 
Microscopically, morphological alterations were 
detected after 24 hours of treatment with CHC. In 
general, cell volume decreased and cells became round 
(Figure 3), possibly due to loss of cell viability. For 
MDA-MB-468, which in normal growth conditions 
has a very round shape (Figure 3E), it was possible to 
observe a more elongated form in part of the 
population (Figure 3F), after CHC treatment. In the 
case of BT20, the morphological alterations were very 
subtle (Figure 3G vs. Figure 3H), anticipating a lower 
sensibility to CHC. 
IC50 values show that MDA-MB-231 is the cell 
line most sensitive to CHC-induced decrease in cell 
biomass (Figure 4E), MCF-7/AZ and MDA-MB-468 
have an intermediate sensitivity to CHC (Figure 4A 
and 4C, respectively), while SkBr3 and Hs578T have 
the highest IC50 value (Figure 4B and 4F, respectively) 
being slightly less sensitive than the formers. For 
BT20, the IC50 was not within the range of 
concentrations used (Figure 4D), thus this cell line 
was considered resistant to CHC, for 24 hours of 
treatment. 
To understand if the inhibitory effect induced by 
CHC in the different cell lines was due to metabolic 
disturbance, glucose consumption and lactate 
production were analysed, using a CHC concentration 
around the IC50 value (5 mM for MDA-MB-231 and 
10 mM for the remaining cell lines), as well as a lower 
concentration (2.5 mM for MDA-MB-231 and 5 mM 
for the other cell lines) to observe if cancer cell 
metabolism is affected, at concentrations inducing a 
reduced effect in total biomass. Quantification of 
extracellular glucose and lactate along time showed 
that MDA-MB-468 is the only cell line where the 
CHC-induced inhibition leads to a significant decrease 
in glucose consumption and lactate production, the 
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latter in a dose dependent manner (Figure 5A and 5D, 
respectively). MCF-7/AZ, SkBr3 and Hs578T 
produced a significantly lower amount of lactate (soon 
after 4 hours for MCF-7/AZ and Hs578T) for both 
CHC concentrations used, and in a dose dependent 
manner for Hs578T (Figure 5B, 5C and 5G, 
respectively), however, this alteration in lactate 
production was not accompanied by a decrease in 
glucose consumption (data not shown). BT20 also 
showed a decrease in lactate production, but only 
when treated with 10 mM of CHC (Figure 5E) and 
also with no decrease in glucose consumption (data 
not shown), while MDA-MB-231 showed no 
alteration in both CHC concentrations at the different 
time points (Figure 5F). 
 
 
DISCUSSION 
We have previously described the up-regulation 
of MCT1 in breast cancer and, importantly, we 
observed that MCT1 was more frequently expressed in 
high-grade tumours, as well as in the basal-like 
subtype [17]. Basal-like tumours have a more 
aggressive clinical behaviour when compared to 
 
 
Figure 4. Effect of CHC in total cell biomass, evaluated by SRB assay. Results are represented as mean±SD. 
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Figure 5. Effect of CHC in MDA-MB-468 glucose uptake (A) and in lactate production in the human breast 
carcinoma cell lines. Results are represented as mean±SEM. 
 
luminal and normal-like breast carcinomas [23-27] 
and, in contrast to the other groups, do not have a 
specific molecular therapy [28,29]. This entails the 
search for new molecular targets in this aggressive 
group of tumours, and, considering the increased 
expression of MCT1 in basal-like tumours as well as 
recent evidence for using MCTs as effective anti-
cancer targets [5,6,8-10], MCT1 emerges as a 
promising therapeutic target, that needs to be further 
explored in breast cancer. 
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In the present work, we analysed MCT1 
expression, as well as the expression of other relevant 
proteins in cancer metabolism, in a variety of human 
breast cancer cell lines. Plasma membrane expression 
of MCT1 was found in MDA-MB-468, BT20 and 
Hs578T, which are basal-like subtype cell lines, being 
in accordance with our findings in human breast 
carcinoma samples [17]. However, in MDA-MB-231, 
another basal-like subtype cell line, MCT1 was not 
detected, as described by others [19,30,31], and the 
same was observed for the luminal subtype cell line 
(MCF-7/AZ) and the HER2 positive subtype cell line 
(SkBr3). The other MCT isoform involved in the 
glycolytic phenotype, MCT4, was strongly expressed 
in some cell lines, namely MCF-7/AZ, SkBr3 and 
MDA-MB-468, however, the immunocytochemical 
staining did not reveal any plasma membrane 
expression. This strong expression of MCT4 may 
reflect the involvement of MCT4 in other cell 
functions, such as in lactate/pyruvate transport through 
the mitochondrial/peroxisomal membranes. Actually, 
MCT4, as well as MCT1, has been described to be 
present in the mitochondrial membrane [32,33]. To 
infer on MCT4 but especially on MCT1 activity, 
CD147 expression was analysed, since proper plasma 
membrane expression and activity of these MCT 
isoforms requires this chaperone [19-21]. However, 
MDA-MB-468 and Hs578T, having a strong plasma 
membrane expression of MCT1, presented low and 
absent CD147 expression, respectively. This indicates 
that CD147 may not be the only chaperone required 
for MCT trafficking to the plasma membrane, 
hypothesis already raised by us and others in previous 
studies [17,34,35]. As expected, since all cell lines 
consume glucose, GLUT1, one of the major glucose 
transporters, was expressed in all cell lines analysed. 
However, GLUT1 staining intensity was not 
associated with the glucose consumption rates 
observed for each cell line, which may be explained 
by the presence of other GLUT isoforms, such as 
GLUT12 [36]. CAIX, which is highly induced by 
hypoxia inducible-factor 1 alpha (HIF-1α), was 
analysed as a surrogate marker of HIF-1α stabilisation. 
Although HIF-1α also induces MCT1, MCT4 and 
GLUT1 expressions [37-39], no associations were 
observed between these proteins and CAIX. Actually, 
focal CAIX expression was only found in MDA-MB-
468, Hs578T and with a very faint staining in MCF-
7/AZ. Probably, if cell lines were cultured up to a 
higher confluence, CAIX would be more extensively 
expressed, as described in confluent but not in sub-
confluent MDA-MB-231 cells [40]. 
Inhibition of lactate transport can be achieved by 
different ways but, considering the outstanding results 
obtained by Sonveaux and colleagues [5] with CHC, 
we decided to use this MCT1 inhibitor in our studies 
in human breast cancer cells.  Importantly, we applied 
a not so conventional assay to determine the inhibitory 
effect of CHC, the SRB assay, since it has been 
described by others that conventional assays like MTS 
or MTT are not adequate when inhibiting MCTs’ 
activity [8]. 
Our results show that the human breast cancer 
cell lines studied have a different response to CHC 
and the underlying mechanisms seem to vary among 
these cell lines. In fact, the most CHC sensitive cell 
line, MDA-MB-231, besides being negative for MCT1 
and producing less lactate then the other lines, showed 
no alterations in glucose consumption or lactate 
production after CHC treatment. Additionally, CHC 
has been described as an effective MCT1 inhibitor in 
vitro and in vivo at concentrations ≥10 mM [9]; 
however, we determined the lowest IC50 for MDA-
MB-231, which is negative for MCT1. These puzzling 
results led us to hypothesise that CHC, in this 
particular cell line, should have other means of action, 
not related to lactate efflux or the glycolytic 
metabolism. CHC has also been described as a potent 
inhibitor of the mitochondrial pyruvate transporter 
[41], however, permeability studies carried out by 
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others show that CHC is not internalised in U-87MG 
glioma cells [9]. Additionally, CHC has also been 
pointed out as an inhibitor of the anion exchanger 1 
(AE1) [42], an important pH regulator that is 
responsible for Cl-/HCO3- membrane exchange [43]. 
Therefore, further studies to unveil the alterative target 
for CHC inhibitory activity are warranted. In contrast, 
MDA-MB-468 and Hs578T, both basal-like, MCT1 
positive cell lines, which consume high amounts of 
glucose and produce high amounts of lactate, suffered 
a significant decrease in glucose consumption (only 
for MDA-MB-468) and lactate production in a dose 
dependent manner, simultaneously with a decrease in 
total biomass. This was the expected result in a highly 
glycolytic cell line after inhibition of MCT1. The 
blockage of lactate efflux likely led to accumulation of 
lactate in the cytoplasm, arrest of glycolysis and 
subsequent decrease in glucose uptake. Inhibition of 
cell proliferation and/or induction of cell death will be 
caused not only by arrest of the metabolic pathway of 
energy production but also due to a decrease in 
intracellular pH, as MCT1 also functions as a pH 
regulator [7]. Additionally, BT20 basal-like subtype 
cell line, although positive for MCT1, was insensitive 
to CHC treatment. This may be due to the low 
glycolytic metabolism of this cell line and dependence 
on other metabolic pathways for energy production. 
The reason why BT20 expresses high levels of MCT1 
in the plasma membrane, regardless of the low 
amounts of lactate produced, remains unclear, but has 
probably to do with the uptake of an alternative source 
of energy from the culture medium, that is also a 
substrate for MCT1, such as pyruvate. Unexpectedly, 
MCF-7/AZ and SkBr3 were sensitive to CHC-induced 
decrease in total biomass in a metabolic dependent 
manner (extracellular lactate was significantly 
decreased, although independent from CHC dose and 
at a lower magnitude than that observed for MDA-
MB-468 and Hs578T), albeit being negative for 
MCT1 expression at the plasma membrane. MCT4 
could be pointed as another target of CHC, however, 
Ki values for MCT4 should be 5-10 times higher than 
for MCT1, ranging the 50 to 100 mM, which is not the 
case observed in this cell lines. 
The results herein presented are very promising 
and need to be completed with other functional 
analysis such as apoptosis, invasion and migration 
assays to further characterise the alterations induced 
by CHC as well as anticipate the practical effect of 
MCT1 inhibition. However, one should always be 
careful when using CHC as a MCT1 inhibitor, always 
confirming the inhibition of the metabolism, avoiding 
looking only to viability and/or proliferating rates. In 
this perspective, other more particular approaches 
such as siRNA or specific MCT1 inhibitors like the 
ones developed by AstraZeneca [44-46] should be 
used. We are currently optimising the use of MCT1 
and MCT4 siRNA to evaluate the effect of MCT 
silencing in cancer cell viability, proliferation, 
apoptosis, invasion and migration. 
The importance of metabolism as a disease 
progression driving force and a strategic therapeutic 
target in cancer has becoming more explored over the 
last years. Evidence provided by experimental data, as 
well as mathematical models, show that the 
hyperglycolytic, acid-resistant phenotype of cancer 
cells, besides providing a growth advantage over 
normal cells, is also critical for the ability of cancer 
cells to invade the surrounding tissue [47-52]. 
Therefore, the targeting of this phenotype will 
probably retard or prevent transition from in situ to 
invasive cancer. Here, by targeting lactate efflux 
through CHC-induced inhibition of MCT1 activity, we 
took a little step forward in the direction to accept 
metabolism targeting as an effective way to control 
tumour and, in particular, to consider the development 
of therapeutic approaches targeting MCT1 as a 
promising strategy to treat basal-like breast tumours. 
However, other in vitro as well as in vivo approaches 
are necessary to confirm these conjectures. 
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6.1. CHAPTER OVERVIEW 
The regulatory mechanisms of MCT expression are far from being completely understood, 
however, regulation by the chaperone CD147 is a well characterised mechanism, supported by 
many in vitro studies [1-8]. Other regulatory mechanisms have also been identified but further 
evidence is needed. One of those alternative mechanisms is MCT regulation by CD44, as only one 
study describes the association between this protein and MCT1, MCT4, as well as CD147 [9]. 
Therefore, a tumour screening was performed aiming to confirm CD44 as a putative 
chaperone of MCTs. For that, CD44 and CD147 expressions, as well as MCT1, MCT2 and MCT4 
were evaluated, in four different types of tumours: breast carcinoma, colon adenocarcinoma, non-
small cell lung cancer and ovarian adenocarcinoma. In this work, published in an international 
periodical with referees, evidence is presented for the possible association of CD44 and MCT1 in 
lung cancer. Further, MCT1 was associated with CD147 in ovarian cancer, while MCT4 was 
associated with CD147 in breast and lung cancer. Notably, a relatively important number of cases 
expressed MCT1 at the plasma membrane of cancer cells but neither CD147 nor CD44 were 
present, suggesting that other mechanisms of regulation for correct trafficking of MCTs to the 
plasma membrane might exist. Also, MCT4 plasma membrane expression was decreased in lung 
cancer, as compared to normal tissue, while MCT1 was expressed in a considerable number of 
ovary tumours, warranting further studies in larger series of these types of tumours.  
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6.2. PUBLISHED RESULTS 
This chapter comprises the following paper, published in an international scientific 
periodical with referees:  
Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F (2010). 
Expression of monocarboxylate transporters 1, 2 and 4 in human tumours and their association 
with CD147 and CD44. J Biomed Biotechnol 2010, Article ID 427694. 
 
  
Chapter 6 Further insights on MCT regulation 
 
 167
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.1. EXPRESSION OF MONOCARBOXYLATE TRANSPORTERS 1, 2 AND 4 IN HUMAN 
TUMOURS AND THEIR ASSOCIATION WITH CD147 AND CD44
  
 
Chapter 6 Further insights on MCT regulation 
 
 169
 
 
 
Role of monocarboxylate transporters in solid tumours Pinheiro C 
 
170  
 
 
 
Chapter 6 Further insights on MCT regulation 
 
 171
 
 
 
Role of monocarboxylate transporters in solid tumours Pinheiro C 
 
172  
 
 
 
Chapter 6 Further insights on MCT regulation 
 
 173
 
 
 
Role of monocarboxylate transporters in solid tumours Pinheiro C 
 
174  
 
 
 
Chapter 6 Further insights on MCT regulation 
 
 175
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7. GENERAL DISCUSSION
  
Chapter 7 General Discussion 
 
 179
 
7.1. OVERVIEW ON THE CONTRIBUTION TO THE STATE OF THE ART 
Carcinogenesis has been viewed as an evolutionary process described as “somatic evolution” 
as it requires a sequence of genetic changes; however, recent models of carcinogenesis integrate 
the neo-Darwinian evolution, stating that phenotypic properties are retained or lost based on their 
contribution to fitness for survival, with cell-environment interactions. This new concept of 
carcinogenesis was applied to explain the Warburg phenomenon, i.e., the preference for the 
glycolytic phenotype, even in the presence of oxygen. Thus, as cancer progression proceeds, 
mutations in tumour cells increase and traits that are found in invasive cancers, like the hyper-
glycolytic and acid-resistant phenotypes, arise as adaptive mechanisms to environmental 
proliferative constraints, such as hypoxia. Many players have been associated with these cellular 
adaptations; however, although an important role of lactate transporters could be anticipated in the 
context of the Warburg effect, the underlying role of MCTs in solid tumours are far from being 
characterised. Although pointed out some times as potential therapeutic targets, information on 
MCTs’ expression in human solid tumours is still very scarce. To be used as therapeutic targets in 
cancer, MCTs must be differently expressed, either in quantity or in isoform. Thus, there is an 
urgent need to determine MCTs’ expression during the carcinogenesis process. Some information 
is provided for human tumours from the nervous system, colon and lung [1-8], but similar studies 
are lacking for other types of tumours. Importantly, only one of these studies analysed the clinico-
pathological value of MCT1 [7]. Also, additional functional studies are needed to comprehend the 
overall contribution of MCTs to tumour malignancy. 
 
 
7.1.1. MCT EXPRESSION IN SOLID TUMOURS 
In this work, an important step forward was taken towards the possibility of exploiting 
MCTs as targets for cancer therapy. In fact, colorectal, cervical and breast carcinomas were found 
to express MCTs, especially MCT1, more frequently than the corresponding normal tissues (Table 
1). 
Importantly, MCT1 was associated with poorer patient prognosis, especially in gastric and 
breast carcinomas. Although MCT1 was not up-regulated in gastric carcinoma, MCT1/CD147 co-
expression was associated with parameters of poor prognosis, such as tumour invasion and 
metastasis, implying a role of MCT1 in tumour aggressiveness. 
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Table 1. Overview on MCT1, MCT2 and MCT4 expression and prognosis in different tumour types. 
Tumour type MCT1  MCT2 MCT4 
Brain 
Strongest in high grade glial 
neoplasms, compared to low grade 
glial neoplasms [2] 
(+) in glioblastoma and (-) in normal 
tissue [5] 
↑ in glioblastoma, compared 
to normal tissue [5] (-) in glioblastoma [5] 
Breast 
↓ due to gene hypermethylation [9] 
↑ in tumour cells, compared to 
normal epithelium / associated with 
basal-like subtype, high histological 
grade, estrogen and progesterone 
receptors, cytokeratins 5 and 14 
and vimentin (alone or co-expressed 
with CD147)  
(+) in tumour cells 
cytoplasm, but not in plasma 
membrane 
(+) normal epithelium  
 
Tendency to be ↑ in tumour 
cells, compared to normal 
epithelium 
Cervical ↑ from preinvasive to invasive / associated with metastases in AC 
(when co-expressed with CD147) 
No progressive change from 
preinvasive to invasive / ↑ 
ASC 
↑ from preinvasive to 
invasive / ↑ AC 
Colorectal 
↓ from normality to malignancy [1,3]  
(+) in tumour cells but (-) normal 
epithelium [6] 
↑ in tumour cells, compared to 
normal epithelium / associated with 
vascular invasion 
Not detected in either normal 
or tumour tissues [3] 
+ in tumour cells cytoplasm, 
but not in plasma membrane 
[6]  
 ↑ in cytoplasm expression 
but ↓ in tumour cells plasma 
membrane compared to 
normal epithelium 
Not detected in either normal 
or tumour tissues [3] 
Weak in tumour 
microenvironment [6] 
↑ in tumour cells, compared 
to normal epithelium 
Gastric 
No change along progression / 
associated with advanced gastric 
cancer, Lauren’s intestinal type, 
stage III+IV and lymph-node 
metastases when (co-expressed with 
CD147) 
 
↓ from normal tissue, to 
primary tumour, to lymph-
node metastases / associated 
with early gastric cancer 
and Lauren’s intestinal type 
Lung 
Cytoplasmic accumulation 
in alveolar soft-part 
sarcoma [4] 
(+) in tumour cells but (-) normal 
epithelium [8] 
(+) in tumour cells and normal 
epithelium 
(+) in tumour cells but (-) 
normal epithelium [8] 
(+) in tumour cells 
cytoplasm, but not in plasma 
membrane 
(+) normal epithelium 
(+) in tumour cells but (-) 
normal epithelium [8]  
↓ in tumour cells, compared 
to normal epithelium 
Ovarian (+) in tumour cells[10] 
(+) in tumour cells 
cytoplasm, but not in plasma 
membrane[10] 
(+) in tumour cells 
Neuroendocrine 
(+) in neuroblastoma / associated with 
age >1 year at diagnosis, stage 4 
disease, unfavourable Shimada 
histopathology, DNA diploid index, 
n-myc amplification and high-risk 
clinical group (COG criteria) [7] 
  
Results from this thesis are shown in bold. ↑, up-regulated;↓, down-regulated; (+) positive, (-), negative. 
Abbreviations: AC, adenocarcinoma; ASC, adenosquamous carcinoma; COG, Children’s Oncology Group. 
 
Additionally, it is important to highlight that both MCT4 and CD147 alone, or MCT1 in 
association with CD147, were more frequently observed in gastric tumours of intestinal-type 
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(Lauren’s classification). This may indicate that the carcinogenic process leading to intestinal-type 
gastric carcinoma, which includes evolution of normal gastric mucosa through chronic gastritis, 
atrophic gastritis (which are common to the diffuse-type gastric carcinogenesis), as well as 
intestinal metaplasia and adenoma/dysplasia (exclusive of the intestinal-type carcinogenesis) [11], 
may require metabolic adaptations involving MCT up-regulation, which are not required during 
carcinogenesis towards diffuse-type gastric carcinomas. Also, in breast carcinoma, an important 
association between MCT1 and basal-like subtype was found. This finding is of great importance 
as, although being a less frequent group of breast tumours, accounting for around 15% of cases 
[12], basal-like subtype tumours have a more aggressive clinical behaviour and, until now, does 
not have a specific molecular therapy. In this scenario, MCT1 arises as a promising therapeutic 
target for this particular group of breast tumours. Considering these findings in the light of the 
microenvironmental model of carcinogenesis, where MCTs shall have a vital role in the 
emergence of both the hyper-glycolytic and acid-resistant phenotypes, one can easily justify the 
up-regulation of MCTs, as well as their contribution to a more aggressive tumour behaviour. By 
enabling lactate efflux from cancer cells, as well as regulate the intracellular pH and, 
consequently, acidifying the extracellular microenvironment, MCT activity will promote the 
aggressive behaviour by enhancing migration, invasion and angiogenesis, among others [13-33].  
Furthermore, in view of the recent model of metabolic symbiosis between glycolytic and 
oxidative cancer cells, where lactate plays a key role as the metabolic intermediate, MCTs are 
essential players in this process. It is proposed in this model that lactate release from 
glycolytic/hypoxic cancer cells occurs through the low-affinity lactate transporter MCT4 and 
lactate uptake by the oxidative/oxygenated cancer cells occurs through MCT1. Moreover, MCT1 
inhibition will lead to a switch from lactate oxidation to glycolysis in oxidative tumour cells, 
thereby preventing the necessary glucose delivery to glycolytic cells, which will die from glucose 
starvation [34]. However, it is important to note that, in the breast carcinoma series herein 
analysed, in contrast to the previous model, MCT1 was expressed in the peri-necrotic/hypoxic 
regions and was expressed in the same cells than the hypoxia markers CAIX and GLUT1, 
important in glycolytic metabolism. This indicates that MCT1, besides being important in 
oxidative cancer cells, may also be important in glycolytic cancer cells. In fact, the kinetic 
parameters of MCT1 make this isoform suitable for both the uptake and efflux of substrates, 
therefore, MCT1 is also appropriate for lactate efflux from glycolytic cancer cells. The role of 
MCT1 in both types of metabolic cancer cells makes it an even more interesting therapeutic target. 
Characterisation of MCT expression in series of human solid tumours provided the first 
evidence of this thesis, suggesting MCT1 as promising therapeutic target for cancer therapy, in 
Role of monocarboxylate transporters in solid tumours Pinheiro C 
 
182  
 
sub-groups of colorectal, cervical and breast carcinomas. However, in this regard, gastric 
carcinoma was an exception as, besides not having MCT up-regulation, MCT4 expression was, 
actually, decreased along progression to malignancy. Therefore, MCT1 will probably not be a 
good therapeutic target in gastric cancer, since is not increased in comparison to the normal tissue, 
but may be an additional marker for prognosis, as it is associated, when co-expressed with CD147, 
to patient’s poor outcome. 
Due to the lack of relevant alterations in the expression of MCT2 in colorectal and cervical 
carcinomas, as well as the lack of associations with clinic-pathological variables, data from this 
MCT isoform expression was not included in the subsequent series. Indeed, MCT2 was also 
evaluated in gastric and breast carcinomas, however with no relevant results (data not shown). 
Importantly, one should never exclude a possible role of MCT2, especially in tumours with non-
glycolytic metabolism. Actually, preliminary results in prostate carcinoma suggest an up-
regulation of MCT2 in tumour cells, as compared to normal epithelium. Importantly, the similar 
specificity and sensitivity of MCT2 staining, as compared with the prostate tumour marker 
AMACR, led to the hypothesis that this MCT isoform may be explored as a new marker of 
prostate carcinoma. 
 
 
7.1.2. MCT REGULATION 
With this thesis, some contribution was also made to understand the possible mechanisms 
underlying MCT regulation. 
Firstly, the regulation of MCT1 and MCT4, but not MCT2, by CD147, was supported by 
evidence on human tissues, complementing the in vitro and some in vivo studies previously 
described by others [35-42]. Indeed, the prognostic value of CD147 appears to be associated with 
its co-expression with MCT1, as observed in breast and gastric carcinomas. Therefore, targeting 
CD147, which will also impair MCT activity, appears to be a rational therapeutic approach against 
human cancer, as already described both in vitro and in vivo [41-43]. Besides the role of CD147 as 
chaperone for MCT1 and MCT4 plasma membrane trafficking and activity, these MCT isoforms 
also have been implicated in CD147 proper membrane expression [38,40]. Thus, the contribution 
of MCTs to the malignant phenotype is not limited to their own function as lactate transporters and 
pH regulators, but may also be further enhanced by their role in regulating CD147 expression. If 
so, MCTs may also have major roles in tumour growth and angiogenesis, as well as cancer cell 
migration and invasion, as described for CD147 [44-46].  
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Additionally, CD44 was analysed as a putative chaperone of MCT1 and MCT4 [47]. 
Although CD44 was only associated with MCT1 in lung cancer, the number of cases was small 
and the results obtained demand further analysis, with a higher number of cases. Indeed, as for 
CD147, which was not associated with MCT1 in the breast carcinoma screening but the tendency 
observed was confirmed in the study with the larger series (with a significant association between 
MCT1 and CD147), CD44 association with MCTs will most likely be also confirmed in larger 
series. As a result, MCT expression may also have a role in cell growth control, adhesion, 
migration, invasion, and chemoresistance [48-50], through interaction with CD44. Importantly, 
although CD147 was associated with both MCT1 and MCT4 in all series analysed, in cervical 
cancer, association was only at the overall expression level and not at the plasma membrane level. 
Additionally, in the other tumour types (gastric and breast carcinoma), there was a relevant 
number of cases with MCT plasma membrane expression that lacked CD147 plasma membrane 
co-expression. Further, in the tumour screening, this absence of CD147 was not overcome by 
CD44. These findings suggest that a not yet identified chaperone may be involved in MCT 
trafficking to the plasma membrane. 
HPV is present in virtually all cervical cancer cases, being a necessary cause for this type of 
cancer [51]. In this thesis, an association between HPV and both MCT1 and MCT4 expression was 
observed in pre-malignant cervical lesions, presenting the first evidence for a possible HPV-
dependent MCT regulation. High-risk HPVs exert their malignant action by constitutively 
expressing two major oncoproteins E6 and E7 [52]. The well-known functions of E6 and E7 are 
that E6 targets p53, resulting in cell resistance to apoptosis, and E7 associates with retinoblastoma 
protein (pRB), promoting cell cycle progression [53]. However, other mechanisms of HPV-
induced carcinogenesis take place, and include activation of transcription factors such as HIF-1α 
and c-myc [54,55]. As these transcription factors are regulators of MCT expression [56-60], one 
can hypothesise that the molecular alterations induced by HPV oncoproteins, which are required 
for cervical carcinogenesis, include up-regulation of MCTs. 
Study on MCT regulation by hypoxia has provided puzzling results, especially in what 
concerns regulation of MCT1 isoform [34,57,58,60-63]. While MCT4 expression has been 
associated with hypoxic conditions and promoter regulation by HIF-1α [58,60-63], MCT1 
regulation by hypoxia points to both directions: induction and repression [34,57,58,60,61,63]. 
Here, additional evidence on MCT regulation by hypoxia is provided, by evaluating the co-
expression of MCTs with the hypoxia-inducible proteins GLUT1 and CAIX, recognised as tumour 
hypoxia markers [64], in breast carcinomas. MCT4, unexpectedly, was not increased in GLUT1 or 
CAIX positive tumours; however, MCT1 was more frequently expressed in both GLUT1 and 
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CAIX positive tumours, pointing to a hypoxia dependent up-regulation of this MCT isoform that is 
accompanied by co-expression of its chaperone CD147. Therefore, it seems that, in breast 
carcinoma, the MCT isoform induced by the hypoxic microenvironment is MCT1, since this 
isoform is present in tumours presenting a hypoxia induced profile, which, in turn, is also 
associated with the basal-like subtype. Importantly, these findings are relevant for the metabolic 
characterisation of basal-like breast tumours, and may have important therapeutic implications as 
new potential targets may arise for this aggressive tumour type. 
 
 
7.1.3. EFFECT OF MCT INHIBITION IN IN VITRO MODELS OF SOLID TUMOURS 
As MCTs play a key role in tumour cell viability and, probably, aggressiveness, some 
groups have performed in vitro inhibition studies targeting MCT expression and activity 
[5,7,34,65,66]. Although with very promising results, these studies are still very scarce and further 
efforts are needed to support the exploitation of MCTs as therapeutic targets. 
Importantly, in this thesis, some in vitro studies were performed for the first time in breast 
cancer cell lines. CHC induced a decrease in total cancer cell biomass, in accordance to results 
described by others in different in vitro models. In the majority of the cell lines, this inhibition was 
accompanied by a decrease in lactate efflux. MDA-MB-468 cell line, presented the most notable 
results, with a CHC-induced inhibition of proliferation, accompanied by a dose dependent 
inhibition of glucose uptake and lactate production. Interestingly, this is a basal-like subtype breast 
cancer cell line, supporting the important role of MCT1 expression demonstrated in the results 
obtained with the breast cancer series. However, this was not observed in all cell lines studied and, 
surprisingly, the most sensitive breast cancer cell line, MDA-MB-231, was negative for MCT1 
and maintained the same level of lactate production and glucose consumption. Therefore, a CHC-
induced inhibition of proliferation that does not have an impact on cancer cell metabolism 
suggests an off-target effect of CHC. In fact, CHC has been described as a potent inhibitor of other 
transporters, such as AE1 [67], but, if those off-target effects of CHC are, in fact, harmful for 
cancer cells as observed in MDA-MB-231, this CHC lack of specificity could actually be an 
advantage, by inducing a more effective cancer cell death. However, to correctly infer on the role 
of MCTs in cancer survival and aggressiveness, more specific inhibitions are needed. One of those 
more directed strategies is the use of siRNAs, which have already shown promising results in 
other models [5,7,34], and some preliminary results in the cervical cancer cell line HeLa point in 
the same direction (data not shown). Also, AstraZeneca MCT1 specific inhibitors currently studied 
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in immunosupression for allotransplantation also anticipate promising results in the cancer 
research field.  
Additionally, it is important to draw attention to the fact that some compounds described as 
MCT inhibitors have been pointed out as chemopreventive agents, such as quercetin, NSAIDs and 
cholesterol synthesis inhibitors (statins) [68-75], as well as effective anti-cancer agents in clinical 
trials, like lonidamine [76]. In fact, NSAIDs and statins were shown to prevent ER-negative breast 
cancer [72,74], which are described in this thesis as having an increased MCT1 expression. Hence, 
MCT1 inhibition may contribute to the chemopreventive and anti-cancer effects of these 
compounds, and further studies on the additional mechanisms underlying their beneficial 
properties are needed. 
When considering MCTs as targets for therapy, it is imperative to bear in mind and evaluate 
toxicity to normal tissue. Systemic delivery of MCT inhibitors, more specifically MCT1, will 
probably affect almost every organ of the body. In skeletal muscle, as MCT1 participates in the 
lactate shuttle, possible side effects will include muscle fatigue and inability to tolerate moderate- 
to high-intensity training due to accumulation of lactate and H+ in the extracellular milieu, as 
oxidative muscle fibers will no longer perform lactate uptake. In the colon, as MCT1 is 
responsible for butyrate transport in colonic epithelium, MCT1 inhibition may inhibit cell 
proliferation and proper differentiation [77]. Importantly, as MCT1 is fundamental for T cell 
activation and, as MCT1 specific inhibition is being studied for immunosupression in 
transplantation, MCT1 inhibition in the cancer context will likely cause immunosupression and 
further inhibition of the immune response against cancer cells. However, in practice, MCT1 
inhibition may have manageable side-effects like myalgia, asthenia, testicular pain, and 
gastrointestinal discomfort, with no serious organ toxicity or myelosupression, as observed for 
lonidamine. Nevertheless, these adverse effects may be decreased or eliminated in association with 
other therapies [76]. Although MCT1 inhibition is prone to cause some important side-effects, one 
should never forget that some drawbacks are acceptable if the benefit is justified, as it happens 
with virtually all drugs. 
 
 
7.2. CONCLUSIONS AND FUTURE PERSPECTIVES 
In general, the results here presented support the hypothesis of a major role of MCTs in the 
emergence of the hyper-glycolytic and acid-resistant phenotypes, as adaptations to the hypoxic 
microenvironment. The up-regulation of MCTs in the plasma membrane of colorectal, cervical 
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and breast cancer cells is most likely an adaptive mechanism to allow continuous high glycolytic 
rates, by exporting the accumulating end-product, lactate, as well as to counteract acid-induced 
apoptosis or necrosis. This may not be the case for all tumour types as gastric carcinoma revealed 
no up-regulation of MCTs. As “aerobic glycolysis” is considered a new hallmark of cancer 
[78,79], and MCTs are key players in the adaptations to hypoxia and acidosis, further efforts 
should be made on the exploitation of these proteins, especially MCT1, as therapeutic targets in 
cancer. 
 
Although much was achieved with this work, many other doors are now open that should be 
explored. Importantly, characterisation of MCT expression in other tumour series would be of 
great value, as additional promising results are anticipated. Ovarian carcinoma, which presented 
high amounts of MCT1 in the tumour screening study, as well as lung cancer that, similarly to 
gastric carcinoma, presented, in opposition to results from other groups [8], a loss of MCT4 
expression, would be two interesting tumour series to proceed with. Additionally, characterisation 
of MCT expression in tumours that are known to have a different metabolic behaviour, such as 
prostate tumours, which rely mainly on fatty acid oxidation rather than glycolysis [80], will also be 
of great interest. Many other tumours, where the contribution of MCTs is still unknown, could 
benefit from additional metabolic studies with evaluation of MCT expression. 
Additional in vitro studies with MCT specific inhibition, evaluating parameters of aggressive 
behaviour, such as migration, invasion and colony formation capacity will shed some light on the 
true value of MCTs. Indeed, MCT4 has already been associated with migration capacity [40,81]. 
Also, by studying the possible contribution of MCT inhibition to the chemopreventive and/or anti-
cancer effects of compounds such as quercetin, NSAIDs, statins and lonidamine, MCTs may stand 
out as important molecular players in cancer and promising therapeutic targets. However, one 
should always bear in mind that the main goal of MCT1 inhibition is the possible clinical 
application, so, MCT inhibitors should be subjected to experimental an clinical studies. 
As an alternative not yet identified chaperone is suggested to be involved in MCT trafficking 
to the plasma membrane, additional studies assessing protein interactions with MCTs may bring 
some new knowledge on MCT regulation. For that, databases of protein interactions would be an 
important tool to explore. 
Besides the more obvious lines that can be further explored, other directions on the 
assessment of the role of MCTs can be taken, such as the study of other metabolic pathways 
important in cancer, like glutaminolysis (where lactate is also produced), microenvironmental 
conditions like acidity and hypoxia, and other players in MCT regulation such as, among others, 
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HIF-1α, AKT, c-myc and, possibly, HPV. Also, other mechanisms by which MCT expression may 
be controlled, including gene mutations or methylation, could also provide relevant information 
regarding MCT tumour alterations. 
Importantly, since cell culture does not mimic all real tumour conditions, including O2 and 
nutrient limitation, key factors in metabolism, it is fundamental to assess the effects of MCT 
inhibition in animal models, in what concerns tumour survival and aggressiveness. Therefore, in 
vivo studies, evaluating the effect of MCT inhibition in, among others, tumour growth, 
angiogenesis and metastisation will be essential. In parallel, as MCTs are also important in 
physiological homeostasis, toxicological studies to determine MCT inhibition side effects will 
determine the real potential of MCTs as therapeutic targets in cancer. 
 
In conclusion, the results herein presented encourage the exploitation of MCTs, especially 
MCT1, as potential targets for cancer therapy, and pave the way for further efforts to understand 
the role of MCTs in solid tumours. Although major advances have been made with the present 
work, it elicits for many other studies to complement the present knowledge on MCTs’ role in 
tumour survival and aggressiveness. 
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